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In neurodegenerative diseases neurons gradually die leading to various symptoms based on 
the affected nervous region. Often memory, movements or both are affected, and the 
symptoms worsen over time greatly affecting the quality of life. Neurodegenerative diseases 
are often caused by many factors, both intrinsic and environmental. Genetics often play an 
important role in neurodegenerative diseases and genetic research can help to elucidate 
disease mechanisms. Since many neurodegenerative diseases share overlapping mechanisms, 
insights in one disease can elucidate the mechanisms of other diseases as well. 
The aim of this thesis was to study the genetics of three neurodegenerative diseases: 
amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD) and the closely related 
dementia with Lewy bodies (DLB). ALS is characterized by a progressive loss of voluntary 
movements that leads to respiratory failure. AD and DLB lead to dementia but DLB patients 
often also have parkinsonism and visual hallucinations. 
In Publication I, we determined the C9orf72 GGGGCC hexanucleotide repeat length of 3142 
Finns. The C9orf72 hexanucleotide expansion is the most common cause of ALS and 
frontotemporal lobar degeneration (FTLD) in populations of European ancestry, but the exact 
pathogenic repeat length and the role of intermediate length alleles in disease is unclear. 
Often 30 repeats is used as the expansion threshold. We presented the distribution of C9orf72 
repeat length in older individuals and found that 0.38% have 30-45 repeats, which is often 
considered to be a pathogenic length. However, these individuals had no apparent 
accumulation of neurodegenerative or psychiatric symptoms. We found no association with 
intermediate repeat length alleles (7-45 or 20-45) and AD or cognitive impairment. 
Intermediate-length alleles with ≥20 repeats were found to be more common in Finland than 
elsewhere. 
In Publication II, we utilized the same cohorts from the first study as controls and additionally 
determined the repeat lengths of 750 Finnish ALS patients and additional 800 younger 
controls aged 18-65 years. There have been mixed results on the association of intermediate 
repeat length alleles with ALS so we tested the association using several thresholds: 7-45, 17-
45, 21-45, 24-45 and 24-30. None of these intermediate repeats associated with ALS when 
only the effect of the longer allele was considered. However, carrying two copies of 
intermediate-length alleles was associated with ALS especially when the longer allele was over 
17 repeats (p=0.002, OR 5.32, 95% CI 2.02-14.05). 
In Publication III, we studied the distribution of Lewy-related pathology (LRP) in the Vantaa 
85+ population cohort. Our results confirmed that LRP progresses caudo-rostrally in 64% 
individuals with LRP, whereas a third have amygdala-based progression pattern. Moreover, 
the amygdala-based progression pattern was associated with AD pathology and APOE ε4. 
These findings are important since APOE ε4 has been the strongest signal in association 




or if the effect is mediated by AD co-pathology. Our findings suggest DLB should not be 
viewed as a single entity, but two. 
In Publication IV, we studied the association of previously identified genetic risk loci for AD 
with the different neuropathological features of AD. These features were amyloid β deposition 
(CERAD score), tau pathology (Braak staging), cerebral amyloid angiopathy and capillary 
amyloid β. We identified risk loci for every neuropathological feature including capillary 
amyloid β for which there were no previously identified risk loci. Our findings help to match 
known AD loci to neuropathological changes elucidating the role of each gene in AD 
pathogenesis. 
The results of this work 1. improve the knowledge of the pathogenic repeat length of the 
C9orf72 expansion, which improves diagnostics and the understanding of ALS disease 
mechanisms, 2. show the high prevalence of the amygdala-based LRP progression pattern and 
the association of APOE ε4 and AD pathology with it, demonstrating two major subgroups in 
DLB that need to be considered in the diagnostics and treatment of DLB patients, and 3. 
demonstrates how AD genetic risk loci associate with AD neuropathological changes including 





















TIIVISTELMÄ (FINNISH ABSTRACT) 
 
Hermorappeumasairauksissa hermosolut vaurioituvat ja vähitellen kuolevat. Oirekuva 
riippuu hermoston vauriokohdista ja rappeutumisprosessin etenemisasteesta. 
Loppuvaiheessa hermorappeumasairaudet vaikuttavat usein merkittävästi sairastuneen 
toimintakykyyn, elämänlaatuun ja minuuteen. Hermorappeumasairaudet ovat yleensä monen 
tekijän summa: niiden syntyyn vaikuttavat perimä ja ympäristötekijät, mutta sairauksien 
tarkat syntymekanismit ovat puutteellisesti tunnettuja, ja hoitokeinoja on vielä vähän. On 
kuitenkin havaittu, että eri hermorappeumasairauksissa on samoja syntymekanismeja ja 
toisinaan myös samoja perimän muutoksia. Näin ollen eri hermorappeumasairauksien 
tutkimuksissa tehdyt havainnot voivat avata uusia tutkimussuuntia ja hoitomahdollisuuksia 
laajemminkin. Perimän muutosten tutkimiseen käytetty teknologia on kehittynyt valtavasti 
2000-luvulla ja sen myötä hermorappeumasairauksien riski- ja taustatekijöistä on saatu 
paljon arvokasta tietoa ja on löydetty jo muutamia hoitokeinojakin. 
Tässä väitöskirjassa tutkittiin kolmea hermorappeumasairautta ja niihin yhteydessä olevia 
perimän muutoksia. Amyotrofinen lateraaliskleroosi (ALS), toiselta nimeltään 
motoneuronitauti, on liikehermojen rappeumasairaus, joka johtaa etenevään 
halvaantumiseen ja kuolemaan. Alzheimerin tauti ja sitä muistuttava Lewyn kappale –tauti 
ovat väestötasolla kaksi yleisintä dementoivaa hermorappeumasairautta. Dementian lisäksi 
Lewyn kappale –tauti aiheuttaa usein myös Parkinsonin taudin kaltaisia liikehäiriöitä ja 
näköharhoja. 
ALS:in yleisin aiheuttaja eurooppalaisessa ja erityisesti suomalaisessa väestössä on C9orf72-
geenissä oleva GGGGCC-toistojakson monistuma (ekspansio). Valtaosalla ihmisistä 
GGGGCC-toistojakso toistuu peräkkäin 2-6 kertaa, mutta ekspansiossa se voi toistua satoja tai 
tuhansia kertoja. Tautia aiheuttava toistojaksojen vähimmäismäärä ei ole tiedossa, mutta 30 
toistojaksoa pidetään usein tällaisena rajana. Myös yli seitsemän toistojakson (ns. 
keskipitkien eli intermediate-alleelien) on raportoitu olevan yhteydessä eri 
hermorappeumasairauksiin. Ensimmäisessä osatyössä määritimme 3142 ikääntyneeltä 
suomalaiselta GGGGCC-toistojaksojen määrän. Tulostemme perusteella 0.38%:lla oli 30-45 
toistojaksoa, vaikka heillä ei ollut viitteitä ALS:ista tai poikkeuksellisen paljon muitakaan 
hermorappeumasairauksia. Tämän perusteella normaalivariaation yläraja on suomalaisilla 30 
sijasta vähintään 45 toistojaksoa, mikä on otettava huomioon määritettäessä toistojakson 
sairautta aiheuttavaa rajaa mm. potilasneuvonnassa. Analyysiemme perusteella 7-45 tai 20-45 
toistojaksoa eivät vaikuttaneet merkittävästi Alzheimerin taudin tai muistihäiriön riskiin 
suomalaisessa iäkkäässä väestössä. 
Toisessa osatyössä selvitimme ensimmäisen osatyön aineiston lisäksi toistojaksojen määrän 
noin 800 suomalaiselta alle 65-vuotiaalta verrokilta ja noin 750 suomalaiselta ALS-potilaalta. 
Tässä ALS-aineistossa GGGGCC-toistojakson ekspansio löytyi 26%:lta potilaista. Aiemmin on 
raportoitu myös 17-30 ja 24-30 toistojakson yhteydestä ALS:iin, mutta nämä havainnot on 
tehty väestöissä, joissa nämä toistojaksot ovat hyvin harvinaisia. Suomessa kyseiset 




pidemmän toistojakson vaikutus huomioidaan. Sen sijaan henkilöillä, joilla oli kaksi 
intermediate-alleelia, oli suurentunut riski sairastua ALS:iin etenkin jos toisessa alleelissa oli 
yli 17 toistojaksoa (p=0.002, OR 5.32, 95% CI 2.02-14.05). 
Kolmannessa osatyössä selvitimme Lewyn kappale –taudissa esiintyvien hermoston 
neuropatologisten muutosten (LRP, Lewy-related pathology) yleisyyttä ja etenemistapaa yli 
85-vuotiaiden suomalaisten väestöpohjaisessa Vantaa85+ aineistossa. Lewyn kappale -
taudissa alfasynukleiini-proteiinia sisältäviä Lewyn kappaleita kertyy eri puolille aivoja. 
Parkinsonin taudissa samoja proteiinikertymiä taas on ensisijaisesti aivojen pohjaosissa. 
Tulosten perusteella pystyimme jakamaan LRP-muutosten etenemistavan kahdeksi eri 
tyypiksi. Toinen on aivojen pohjaosista ylöspäin etenevä muoto (caudo-rostral, 67% 
tapauksista) ja toinen on lähtöisin mantelitumakkeesta aivojen keskiosilta (amygdala-based, 
32% tapauksista). Vain 1% tapauksista jäi luokittelun ulkopuolelle. Mantelitumakkeesta 
alkavat LRP-muutokset esiintyivät Alzheimerin taudin neuropatologisten muutosten kanssa 
ja liittyivät tunnettuun Alzheimerin taudin geneettiseen riskitekijään APOE ε4:ään. Sen sijaan 
aivojen pohjaosista alkavat LRP-muutokset (caudo-rostral) esiintyivät Alzheimer-patologiasta 
ja APOE ε4:stä riippumattomasti. Tulostemme perusteella Lewyn kappale -taudilla on siis 
todennäköisesti kaksi neuropatologisesti ja geneettisesti erilaista alatyyppiä. 
Neljännessä osatyössä selvitimme, miten Alzheimerin tautiin yhdistetyt 29 perimän 
riskilokusta liittyvät erityyppisiin Alzheimerin taudin neuropatologisiin muutoksiin. Tutkitut 
neuropatologiset muutokset olivat: 1. amyloidi β-peptidin kerääntyminen hermosolujen 
ulkopuolelle (CERAD score), 2, amyloidi β-peptidin kertyminen verisuonien seinämiin, 3. 
amyloidi β-peptidin kertyminen hiussuoniin ja 4. tau-proteiinin kerääntyminen hermosolujen 
sisään (Braak stage). Havaitsimme, että osalla Alzheimerin taudin perimän riskikohdista oli 
yhteys kaikkiin eri neuropatologisiin muutoksiin (esimerkiksi APOE), kun taas osalla oli 
yhteys vain tiettyyn neuropatologiseen muutokseen. CASS4-, CLU-, ja ZCWPW1-geenien 
muutokset liittyivät spesifisti amyloidi β-peptidin kertymiseen verisuonien seinämiin. 
Amyloidi β-peptidin kertyminen hiussuoniin liittyi TREM2-geeniin. TREM2 liittyy 
puolustussolujen aktivaatioon ja löydöksemme hiussuoniin kertyvän amyloidi β-peptidin 
suhteen saattaa selittyä riskialleelien vaikutuksella immuunijärjestelmän solujen toimintaan. 
Tämä väitöskirjatyö 1. tarkensi tietämystä C9orf72-geenissä olevan toistojakson 
normaalivaihtelusta ja tautia aiheuttavasta toistojaksojen määrästä, mikä auttaa 
diagnostiikassa ja ALS:in tautimekanismien ymmärtämisessä, 2. osoitti, että Lewyn kappale –
tautimuutokset etenevät kahdella tavalla viitaten kahteen geneettiseltä alttiudeltaankin 
erilaiseen alatyyppiin, jotka ovat tärkeä erottaa Lewyn kappale -taudin jatkotutkimuksissa ja 
mahdollisesti potilaiden hoidossa, 3. ja näytti, että Alzheimerin tautiin liitettyjä perimän 
muutoksia voidaan yhdistää tiettyihin neuropatologisiin muutoksiin, mikä auttaa 
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The human nervous system is complex and can be divided into the central nervous system 
(CNS) and the peripheral nervous system (PNS). The CNS includes the brain and spinal cord 
and PNS the peripheral nerves that e.g. control muscles. Not all types of neurons are affected 
in one neurodegenerative disease, instead, typically specific neuron populations are affected. 
Thus, the clinical spectrum of neurodegenerative diseases is vast and reflects the parts of the 
nervous system that are affected by pathogenic processes. For example, in amyotrophic lateral 
sclerosis (ALS) the motor nerves in the CNS and PNS die leading to the gradual loss of 
voluntary movements. However, cognition remains unaffected in ALS patients if the brain 
regions involved in cognitive processes are left intact. On the other hand, in Alzheimer’s 
disease (AD) where the neurons of the hippocampus and entorhinal cortex are among the first 
to be affected, cognition and memory are impaired but movements can remain normal. In 
dementia with Lewy bodies (DLB), there is both loss of cognition and impairment of 
movements. 
Neurodegeneration can be caused by many factors, both intrinsic and extrinsic. It is a slow 
process and can take from months to decades. For example, alcohol abuse leads to changes in 
both the CNS and PNS in the forms of cerebellar degeneration and peripheral neuropathy. In 
AD, the preclinical stage of the pathological evolution often starts in middle age (40-50s) 
whereas patients are usually diagnosed after their late sixties (Kok et al., 2009; Rajan, Wilson, 
Weuve, Barnes, & Evans, 2015). 
The high number of potential causes, the extensive time the disease takes to develop, and the 
complexity of the nervous system have made the study of neurodegenerative diseases 
challenging. Neuropathological studies that characterize the changes in the nervous system 
have been crucial in building modern understanding of neurodegenerative diseases. For 
example, Alois Alzheimer described amyloid β (Aβ) depositions in the brain in 1906, and in 
1962 the topography of neurofibrillary structures were reported (Hirano & Zimmerman, 
1962). In 1986, phosphorylated tau was identified as the key component in neurofibrillary 
tangles (Kosik, Joachim, & Selkoe, 1986). Later, genetic studies tied together the 
neuropathological observations to show that the observed neuropathological changes can be 
attributed to genetic mutations, helping to explain the pathogenic mechanisms on a molecular 
level. Important milestones were the purification and characterization of  Aβ in 1984 (Glenner 
& Wong, 1984) and the cloning of the APP gene in 1987 (Kang et al., 1987). The first APP 
mutations found to cause early-onset AD were reported in 1991, with PSEN1 and PSEN2 
mutations in 1995 (Chartier-Harlin et al., 1991; Levy-Lahad et al., 1995; Sherrington et al., 
1995). 
During the last decade, the role of genetics in research has become increasingly important 
thanks to new technologies. Instead of studying families with specific high impact mutations, 
researchers have also been able to study the genetics of thousands of cases and controls 
simultaneously. These genome-wide association studies have allowed for the identification of 




the Psychiatric Genomics Consortium, 2014) where there is no one major mutation but many 
variants across multiple loci together with environmental factors affecting the phenotype. 
When genome-wide association studies are conducted on next-generation sequencing data, it 
can allow rapid detection of causal variants in a population.  
Genetics as a field has advanced tremendously over the last few decades: the human genome 
project took over a decade and over 3000 million US dollars whereas now a whole genome 
can be sequenced in a day for under 2000 dollars. Despite this progression and significant 
effort, disease-modifying treatments for neurodegenerative diseases are scarce. To date, the 
vast majority of interventions are symptomatic: they can lessen the symptoms but cannot 
alter the course of the disease. However, with simultaneous advancements in pathological 
methods, imaging technologies and the continuing advancements in genetics, 
neurodegenerative diseases can be studied in a much more comprehensive manner than 
before and disease-modifying treatments are on the horizon. 
The aim of this work was to further study the genetics of three neurodegenerative diseases: 
ALS, AD and the closely related DLB. Improved knowledge of disease genetics can elucidate 
disease mechanisms, which can translate to a better understanding of how diseases progress 




















2. REVIEW OF LITERATURE 
 
2.1. The human genome and genetic variation 
 
2.1.1. The human genome 
 
The first draft of the human genome was published in 2001 (Gamba, 2001) and the project 
was finished a couple of years later (International Human Genome Sequencing Consortium, 
2004). This genome sequence (build, i.e. version 35) consisted of 2.85 billion nucleotides and 
an estimated 20 000 – 25 000 genes, but had several hundred gaps. Since then, the reference 
genome has been updated and the latest major version (build 38) was released in December 
2013. It consists of 3 billion base pairs on 22 autosomes, two sex chromosomes and 
mitochondrial DNA. Despite major improvements, there are still gaps and sequences on 
unlocalized chromosomal areas or scaffolds.  
Only 1% of the human genome encodes proteins and the rest has been historically regarded as 
“junk DNA” but this belief is nowadays largely questioned. The non-coding regions and their 
roles in both health and disease are still largely unknown, although some important functions 
are known. For example, it has been reviewed that transcriptional enhancers and long non-
coding RNA play important roles both in normal physiology, development and disease (Lee, 
H., Zhang, & Krause, 2019; Nord & West, 2019). 
 
2.1.2. Genetic variation 
 
The simplest and most common type of genetic variation is single nucleotide variation (SNV) 
or single-nucleotide polymorphism (SNP), where one base is different compared to the 
reference genome (Figure 1). In a typical genome, there are roughly 3-4 million SNVs (Shen et 
al., 2013), thus only an extremely rare number of SNVs are pathogenic. The majority of SNVs 
are very rare at a population level and the number of identified rare variants has increased 
tremendously as more genomes are sequenced. For example, in the 1000 Genomes dataset 
with 2500 genomes, there were 85 million SNVs from which 64 million SNVs had a minor 
allele frequency (MAF) <0.5% whereas there were 8 million SNVs with a MAF > 5% (1000 
Genomes Project Consortium et al., 2015). In the gnomAD version 3 dataset with 20314 
genomes, there were more than 200 million SNVs but the number of common variants with a 
MAF > 5% was roughly the same 8 million (Karczewski et al., 2020). 
Indels are small (less than 50bp) insertions or deletions and like SNVs they are abundant, 
with roughly 0.4-0.5 million per genome (1000 Genomes Project Consortium et al., 2015). 
The large number of SNVs and indels pose a challenge in genetic studies trying to identify 
pathogenic variants since there are over 100 protein truncating variants caused by SNVs and 




Larger insertions and deletions, as well as different rearrangements and copy-number 
variations are called structural variants (SVs). SVs are more often pathogenic than smaller 
variations, but they are also much rarer. In the 14891 individuals with deep whole-genome 
sequencing data of the Genome Aggregation Database (gnomAD), there were around 8000 
SVs per genome and as a consequence, on average eight genes were altered by rare SVs 
(Collins et al., 2020). 
Another type of variation is tandem repeat variation, e.g. short tandem repeats (STRs) where 
there is a repeat unit of 1-6 base pairs. STRs are almost as common as indels in the genome 
and there are more than 30 hereditary diseases caused by STRs, for instance Huntington’s 
disease, fragile X syndrome and myotonic dystrophy. The repeats lead to changes in gene 
expression and accumulation of RNA and repeat peptides. Often the number of repeats 
increases in offspring leading to genetic anticipation, i.e. the disease begins earlier and is 
more severe in each subsequent generation (McComas, Sica, & Toyonaga, 1978; Mirkin, 
2007). 
The variations above change the base pair sequence of DNA but there is also variation where 
the DNA sequence remains intact. Epigenetic changes affect the chromatin state and thus 
transcription, without changing the DNA sequence. Methylation of DNA was one of the first 
epigenetic modifications observed (Gold, Hurwitz, & Anders, 1963), other common epigenetic 
changes include histone modifications (Cavalli & Heard, 2019). Epigenetic modifications are 
an important reminder that although DNA is often studied as a two-dimensional sequence of 
bases, it is a complex three-dimensional structure. 
 
2.1.3. Genotyping and sequencing technologies 
 
Modern sequencing technologies allow high-throughput studies with decreasing costs. 
Commonly used methods include genome-wide genotyping assays, whole-exome (WES) and 
whole-genome sequencing (WGS). Genotyping arrays include a variable number of markers 
preselected to capture the genetic variation with typically 0.5 – 3 million markers. Albeit 
genotyping chips rarely include pathogenic variants, they are a cost-effective way of 
conducting genome-wide association studies and some arrays also enable large CNV 
detection. Furthermore, genotyping arrays can be used to impute missing genotypes. 
Imputation is a method where missing genotypes are inferred based on haplotypes from a 
reference sample. Imputation is very accurate with common (MAF > 5%) variants but good 
results can be achieved for rare variants as well, especially when using sufficiently large 
ancestry-matched reference panel (Mitt et al., 2017).  
WES targets the exons, i.e. the protein coding part of the genome. Since many disease-causing 
variants are exonic, it is a more cost-effective way compared to WGS to find likely pathogenic 
mutations in Mendelian diseases. As costs come down, WGS has become widely used. It also 
covers non-exonic regions and gives a much more detailed picture on individual genetic 




are established guidelines for determining the likelihood of the pathogenicity of variants in 
exonic regions (Richards et al., 2015), but the classification of non-coding variants is still 
difficult. Typically, short-read WGS is used and allows for excellent detection of SNVs, indels 
and performs well with some structural variants. However, to more reliably capture complex 
structural variants such as complex rearrangements or tandem repeats, it is advisable to use 
long-read WGS (Lappalainen, Scott, Brandt, & Hall, 2019). 
 
 
Figure 1: A) Examples of small genetic variations. First is an imaginary reference sequence, followed by an SNV 
where there is a point mutation of a single base. Following these, a small insertion and a small deletion are 
shown, followed by a short tandem repeat (GGGGCC). B) DNA methylation at GpC does not change the base pair 





Currently, short-read sequencing and sequencing-by-synthesis is the most widely used 
method of next-generation sequencing (NGS). A typical sequencing workflow includes four 
steps. First, library preparation includes DNA fragmentation into smaller pieces to which 
adapters are ligated. The second step is known as cluster generation where the library is put 
on the sequencing machine’s flow cell and adapters on the DNA bind to the surface of the flow 
cell. Clusters, i.e. groups of “clones” of attached sequences are generated using bridge 
amplification. The third step is the sequencing where the bases are identified based on the 
signal they send. Cluster formation enables the signal to be strong enough for accurate 
capture. The final step is the data analysis, where quality control of the sequencing reads is 
performed and the usually billions of sequencing reads are aligned to the reference genome 
for identification of genetic variants. 
 
2.1.4. Genome-wide association studies 
 
Genome-wide genotyping and sequencing technologies allow genome-wide association 
studies (GWAS) (Visscher et al., 2017). In a GWAS, typically hundreds to thousands of 
unrelated individuals are studied in order to find loci that associate with different phenotypes. 
The results are often presented as a “Manhattan plot” (Figure 2). However, even if a 
statistically significant association is found, the effect size or odds ratios of an individual locus 
on the phenotype tend to be small (typically < 1.3) in complex diseases. Still, when the effect 
of many individual loci with small effects are considered together, the loci can explain 
together a significant amount of phenotypic variance. For example, adult height is a complex 
polygenic trait in which circa 700 variants explain reportedly 20% of its heritability (Wood et 
al., 2014). One application of summarizing the effects of individual loci is the polygenic risk 
score (PRS) that can be calculated for various phenotypes. Moreover, the identification of new 
loci even with small effect sizes can give valuable information on diseases via pathway 
analysis. Pathway analysis is based on prior knowledge of gene function. For example, loci 
associated in a recent large AD genome-wide association analysis were enriched in pathways 
involved in e.g. degradation of amyloid precursor proteins and lipid metabolism (Jansen et 
al., 2019). 
However, the association between an identified locus and the biology of the disease is often 
complex and although GWASes have successfully identified thousands of loci, how the 
observed associations translate into disease is often unknown. After sufficient replication to 
find true associations, functional “post-GWAS” studies are needed to elucidate the role of 
observed variants (Gallagher & Chen-Plotkin, 2018). One major hurdle in understanding the 
effects of GWAS results is that the top association is rarely the causal variant since variants on 
genotyping arrays are mostly selected based on haplotype structure. Rather, due to linkage 
disequilibrium (LD), it flags the haplotype that associates with the disease. Moreover, if the 
top hit is in an intergenic area, the gene of interest can be unclear. One example of a common 
post-GWAS functional method is to study the overlap of a putative causal variant with the 
expression levels of different genes. This is especially useful if the suspected causal variant is 




development of gene editing technology, the effects of haplotypes or individual SNPs can also 




Figure 2: Manhattan plot. On the y-axis is the –log10 of the P-value and on the x-axis are the genomic positions 
of every variant per chromosome. Each dot represents one variant. In GWAS, due to multiple testing correction, 
only p-values less than 5x10-8 are regarded as statistically significant. This threshold is represented as a 
horizontal line. The name of the plot is a reference to the skyline of Manhattan with the association peaks as 
skyscrapers. This picture is based on the “gwasResults” data supplied with the “qqman” package of R (Turner, 
S.D. qqman: an R package for visualizing GWAS results using Q-Q and manhattan plots.) 
 
2.1.5. Finnish population genetics 
 
Finnish population genetics have some unique features owing to our history and how people 
settled in Finland. There are many theories about how migration, agriculture, wars etc. 
affected the early Finnish population. Be that as it may, the genetic composition today is most 
likely affected by a founder effect in addition to several bottlenecks caused by epidemics and 
famine. Geographical isolation has made Finns a genetically homogenous population but e.g. 
there is a notable east-to-west difference that has been extensively reviewed (Norio, 2003b; 
Palo, Ulmanen, Lukka, Ellonen, & Sajantila, 2009), as well as regional subpopulations 
(Kerminen et al., 2017). The east-to-west difference has been suggested to at least partially 
reflect the two main waves of settlement: first the western parts along the coast, then to the 
eastern and northern regions (Norio, 2003b). 
From a genetic perspective, Finns are outliers of European populations, as are people from 




Genotyping some 50 000 - 200 000 SNPs already enables visualization of European genetic 
structures using principal component analysis (PCA). However, in a global context, Finns 
clearly cluster with other European populations (Figure 3). Modern technologies paired with 
population registry data allow much more precise analyses on genetic structure than standard 
nation-level comparisons. The Finnish genetic structure was fine mapped in 2017 (Kerminen 
et al., 2017). It showed that the fine structure is strongly geographically clustered across 
Finland and that the main split is indeed the historical east-west axis. Knowing the fine 
structure has its own academic value but it also has applications e.g. in rare variant 
association studies where population substructure can become a confounding factor 
(Mathieson & McVean, 2012). 
The Finnish disease heritage is one example of the unique Finnish population genetics. The 
Finnish disease heritage consists of over 30 diseases that are seen in Finland but are rare or 
absent in other populations such as cartilage-hair dysplasia and polycystic lipomembranous 
osteodysplasia with sclerosing leukoencephalopathy. Most of these diseases are inherited 
recessively and for most the genetic cause is also known. On the other hand, some diseases 
such as cystic fibrosis are considerably rarer in Finland than elsewhere (Norio, 2003a). 
In addition to Finnish disease heritage, some other pathogenic variations of more common 
diseases are overrepresented in Finland. Examples include the C9orf72 hexanucleotide repeat 
expansion that causes ALS and frontotemporal lobar degeneration (FTLD) (Majounie, Renton 
et al., 2012)  and the deletion of exon 16 in MLH1 in hereditary nonpolyposis colon cancer 







Figure 3: PCA of European populations and smaller picture of global PCA. On the x-axis is the 1st principal 
component and on the y-axis the 2nd. Each dot represents one individual. On the lower big plot are individuals of 
European ancestry and Finns form a separate cluster. However, in a global context, Finns cluster with other 
Europeans as seen in the smaller plot. Populations: CEU = Utah Residents with Northern and Western European 
Ancestry, FIN = Finns, GBR = British in England and Scotland, IBS = Iberian in Spain, TSI = Toscani in Italy. 
Superpopulations: AFR = African, AMR = Admixed American, EAS = East Asian, EUR = European, FIN = Finns, 
SAS = South Asian. Data from phase III of the 1000 genomes project (1000 Genomes Project Consortium et al., 
2015). 
 
2.2. Aging and neurodegeneration 
 
Aging, the gradual decline of an organism’s function over time, is an inevitable part of life. 
From a broader sense, aging is caused by cellular damage (Kirkwood, 2005). Aging is a very 
complicated process but the accumulation of cellular damage has been summarized as being 
due to nine partially overlapping hallmarks: genomic instability, telomere shortening, 
epigenetic alterations, loss of protein homeostasis (proteostasis), deregulated nutrient 
sensing, mitochondrial dysfunction, cellular senescence (cell cycle arrest, inability to produce 
daughter cells), stem cell exhaustion and altered intercellular communication (Lopez-Otin, 
Blasco, Partridge, Serrano, & Kroemer, 2013) (Figure 4). Since aging is the strongest risk 
factor for many neurodegenerative diseases (Duggan, Torkzaban, Ahooyi, Khalili, & Gordon, 
2019), it is natural that there is considerable overlap between the mechanisms of 




the body’s mass but consumes about 20% of our daily energy (Rolfe & Brown, 1997). Due to 
this high metabolic rate, neurons are susceptible to pathological changes in cell metabolism 
that lead to cellular damage and neurodegenerative diseases. Moreover, neurons are post-
mitotic by nature, which resembles permanent cell cycle arrest, i.e. cellular senescence, one of 
the hallmarks of aging. 
 
 
Figure 4. The hallmarks of aging. The different hallmarks are not separate entities but overlap. The hallmarks are 
present in normal aging, and their amelioration or aggravation slow down or accelerate aging, respectively. Both 
endogenous and exogenous processes affect aging. For example, mutations in DNA occur in normal DNA 
replication but UV-radiation can also cause them. Many of these hallmarks are the same as the molecular 
mechanisms behind neurodegeneration. Image redrawn and modified from (Lopez-Otin et al., 2013). 
 
Neurodegenerative diseases can be classified in various ways, e.g. by the predominant 
symptom or location of the predominant lesion (Przedborski, Vila, & Jackson-Lewis, 2003). 
Although many neurodegenerative diseases show considerable overlap and symptoms vary, 
dementia is one major endpoint of neurodegeneration. WHO has estimated that in 2030 there 
will be more than 80 million people with dementia and this number increases to 150 million 
in 2050. In 2015, WHO estimated that dementia leads to a cost of over 800 billion dollars and 
this cost will increase to over 2000 billion dollars in 2030 (https://www.who.int/news-
room/fact-sheets/detail/dementia). The humane cost of dementia is in the loss of good 




Despite dementia being a major endpoint (and perhaps the best-known one for larger 
audiences), not all neurodegenerative diseases lead to dementia, rather, clinical features 
reflect the damaged part of the nervous system. The symptoms vary based on the affected 
regions and do not always include dementia or cognitive disturbances but rather muscle 
weakness, spasticity, muscular atrophy or rigidity as in ALS, spinal muscular atrophy and 
different ataxias (Table 1). 
 
Table 1. The most severely affected regions of the nervous system in different neurodegenerative diseases. 
Disease Most severely affected region 
Alzheimer's disease Cerebral cortex (medial temporal lobe) 
Dementia with Lewy bodies Cerebral cortex, amygdala, substantia nigra 
Parkinson's disease Substantia nigra 
Amyotrophic lateral sclerosis Motor neurons and interneurons (CNS and PNS) 
Frontotemporal dementia Frontal and temporal lobes 
Polyneuropathies Peripheral motor and sensory neurons 
Spastic paraplegias Motor neurons (CNS) 
Spinocerebellar ataxias Cerebellum (spinal cord) 
  
 
Neurodegeneration is often accompanied by the accumulation of misfolded proteins that 
demonstrates the dysfunction of proteostasis. Neurodegenerative changes accumulate with 
age and are present even in cognitively unimpaired individuals more as a rule than as an 
exception. A summary of pathological studies concluded that in the brains of individuals older 
than 80 years, hyperphosphorylated tau was present in over 90% and Aβ in over 60% and the 
prevalence of mixed pathology also increased with age (Elobeid, Libard, Leino, Popova, & 
Alafuzoff, 2016). There is often, however, a distinction between changes seen in “normal” 
aging versus pathological neurodegeneration. In disease, neurodegeneration is considered to 
be present in major neuronal circuits and there is cell specific vulnerability (Morrison & Hof, 
1997). For example, in mild AD there is already a loss of up to 50% of neurons in layer II of 
the entorhinal cortex compared to no loss in neurologically healthy individuals (Morrison & 
Hof, 1997). 
Whether the different proteins that accumulate in the brain are a by-product of 
neurodegenerative processes or their cause remains unclear. Nevertheless, it has been 
reviewed that the accumulation of such proteins points to problems in protein degradation as 
a key mechanism not only in aging but also in neurodegeneration (Haass & Selkoe, 2007).  
Besides changes in protein homeostasis, the mechanisms of neurodegeneration are many and 
are thought to include for example DNA damage, lysosomal dysfunction, epigenetic changes 
and immune dysregulation (Katsnelson, De Strooper, & Zoghbi, 2016). To some extent, these 
are a part of normal aging but in disease these mechanisms are altered or advance at a much 




As previously stated, there is considerable overlap between the mechanisms of aging and 
neurodegeneration and genetics has had an important role in studying the two phenomena. 
Apolipoprotein E (APOE) was one of the main associations in recent longevity meta-analysis 
(Deelen et al., 2019) and it has also been associated with several neurodegenerative diseases 
such as AD (Strittmatter et al., 1993) and DLB (Guerreiro et al., 2018) but also in 
cardiovascular and renal diseases (Feussner et al., 1992; Ghiselli, Schaefer, Gascon, & Breser, 
1981). It has three main genotypic variants: ε2, ε3 and ε4. ε3 encodes the major isoform 
followed by ε4. ε4 is the disease associated variant, whereas ε2 is protective and ε3 is regarded 
as neutral. There is also evidence that certain regulatory variants at the APOE locus modulate 
the risk of AD and cognitive decline, independent of the protein polymorphism (Myllykangas 
et al., 2002; Rantalainen et al., 2016). APOE mediates lipid transfer but also binds to different 




2.3. Dementia with Lewy bodies 
 
2.3.1 Definition and epidemiology 
 
DLB has not been recognized as a separate and distinct disease for long; only in 1984 was it 
proposed as its own disease entity (Kosaka, Yoshimura, Ikeda, & Budka, 1984) and the first 
international consensus criteria for its diagnosis were published in 1996 (McKeith, I. G. et al., 
1996).  
DLB is a synucleinopathy, a neurodegenerative disorder characterized by the accumulation of 
α-synuclein. A subcategory of synucleinopathies are Lewy body diseases where α-synuclein 
aggregates into Lewy bodies and Lewy neurites, collectively called Lewy-related pathology 
(LRP). The most common Lewy body diseases have been reviewed to be DLB, PD and 
Parkinson disease dementia (PDD) (Jellinger, 2003). 
As can be deduced from its late discovery, DLB often clinically resembles other 
neurodegenerative diseases such as AD and PD and it can sometimes be differentiated by 
PDD only by “the one year rule”. This rule dictates that in DLB dementia precedes or is 
concomitant with parkinsonism whereas in PDD dementia begins at least one year later than 
motor symptoms (Yamada et al., 2019). DLB has been “overshadowed” by AD and PD and this 
has led to poor general knowledge of the disease and also under-diagnosis of DLB (Vann 
Jones & O'Brien, 2014) that has held back research. 
With increasing awareness and knowledge of the disease, DLB is now considered the second 
most common primary dementia after AD but estimates of its prevalence vary greatly. In 
population studies of those over 65 years, mean prevalence was 0.36% whereas <7.5% in 




DLB was published in 2003 (Rahkonen et al., 2003). They studied 601 individuals from the 
Kuopio region, aged at least 75 years and found the prevalence of DLB to be 5% or 22% among 
all individuals with dementia. For comparison, in the same study, the prevalence of AD was 
10.6% representing 47% of all dementias. LRP is much more common than actual DLB and it 
was present in more than a third of Finnish individuals aged over 85 years (Oinas et al., 
2009). 
Risk factors for DLB seem to partly overlap with those of AD and PD. The strongest risk factor 
is advanced age, and DLB is more common in men than in women. Family history of 
dementia, a history of depression and anxiety increased the risk of DLB, whereas caffeine use 
and a history of cancer reduced it (Boot et al., 2013). Whilst lower education correlates with 
AD, higher education correlates with DLB and PD (Guerreiro et al., 2019). 
 
 
2.3.2. Neuropathology and molecular mechanisms 
 
A key molecular mechanism behind DLB like other synucleinopathies is thought to be the 
abnormal aggregation of α-synuclein. α-synuclein is coded by the SNCA gene on chromosome 
4. The initial nucleation process is the rate-limiting step of fibril formation but preformed 
oligomers and fibrils can speed up formation of new aggregates (Iljina et al., 2016). The 
mature fibrils might not be behind toxicity but the pathological changes and eventual 
neuronal loss could be due to heterogeneous oligomers, of which some have been shown to be 
highly neurotoxic (Grassi et al., 2018). It has also been shown that α-synuclein can spread 
from cell-to-cell much like prions (Desplats et al., 2009). Despite considerable effort, the 
normal physiological function of α-synuclein is not clearly understood. α-synuclein knock-out 
mice are viable and do not show evident neurodegeneration early on but there are changes at 
the synapses that increase with age (Greten-Harrison et al., 2010). Therefore, in disease 
development, the overexpression and misfolding of α-synuclein has been upheld as important 
(Thakur, Chiu, Roeper, & Goldberg, 2019).  
In tissues, α-synuclein can be visualized using immunohistochemistry, which allows the 
detection of LRP. Loss of dopaminergic neurons in the substantia nigra, Lewy neurites and 
intracytoplasmic Lewy bodies in surviving neurons are key neuropathological changes in DLB 
and PD (McKeith, I. G. et al., 1996). In DLB, there are often also widespread neocortical Lewy 
bodies. With the new 5G4 α-synuclein antibody, Lewy neurites are also observed in areas that 
have not yet developed Lewy bodies (Kovacs et al., 2012). Based on a semiquantitative 
approach, LRP can be staged or categorized in several ways. Two widely used classification 
schemes are Braak staging (Braak et al., 2003) and the DLB Consortium classification 
(McKeith, I. G. et al., 2017). In Braak staging, LRP is thought to progress caudo-rostrally i.e. 
from brainstem towards neocortex. However, this staging fails to explain increasing 
observations that LRP can be seen only in limbic regions, especially in adjunction with AD 




observations have raised speculations of a distinct AD associated synucleinopathy (Uchikado, 
Lin, DeLucia, & Dickson, 2006). The new DLB consortium classification acknowledged these 
observations by adding an amygdala predominant group but categorized it as a low likelihood 
sign of DLB. To date, it is not known, how common this AD associated synucleinopathy is in 
the general population since previous studies have used disease cohorts or study participants 
were recruited from specialized centers, leading to referral bias. It is also unknown if there are 
genetic differences that separate this LRP type from other LRP types and why some develop it 




Figure 5. A. Caudo-rostral progression of LRP and B. hypothesized amygdala-based spreading in the “Alzheimer 
associated synucleinopathy”. C. Microscopic image of LRP where arrow a shows a Lewy body and arrow b a Lewy 
neurite. Original picture “Photomicrographs of regions of substantia nigra in this Parkinson's patient show Lewy 
bodies and Lewy neurites in various magnifications” by Suraj Rajan modified and reprinted under the creative 
commons license CC BY-SA 3.0. 
 
It is noteworthy that the mixed pathologies of AD and DLB most likely do not develop 
irrespective of one another (Figure 6). It has been shown that overexpression of α-synuclein 
can promote beta-secretase activity, leading to enhanced cleavage of Aβ from its parent 
protein increasing the secretion of Aβ (Roberts, Schneider, & Brown, 2017). Moreover, it has 




develop prominent neurodegeneration and enhanced α-synuclein accumulation (Masliah et 
al., 2001). Furthermore, the injection of α-synuclein fibrils in mice with prominent Aβ plaque 
pathology clearly accelerated α-synuclein pathology. This led to spreading of α-synuclein 
pathology and neuron loss (Bassil et al., 2019). In neurodegenerative diseases with mixed 
pathologies, the different pathological features seem to interact and can form a vicious cycle 
where they enhance one another. Due to the high prevalence of APOE ε4 in AD and common 
co-occurrence of AD and DLB, the effects of APOE on α-synuclein pathology is under intense 
investigation. Of special interest is whether APOE is an independent driver of α-synuclein 
pathology. There are both mouse and human studies that support this hypothesis. Two recent 
studies that used human α-synuclein transgenic mice expressing different human APOE 
isoforms, presented evidence suggesting APOE ɛ4 regulates synucleinopathies directly and 
independently of amyloid deposition (Davis et al., 2020; Zhao et al., 2020). There are also 
human studies that reported APOE association with LBD independent of AD pathology 
(Dickson et al., 2018; Tsuang, D. et al., 2013; Zhao et al., 2020). However, the sample sizes of 
these studies have been small and used variable inclusion and exclusion criteria. Moreover, 
there are some studies that did not observe APOE associating with DLB independent of AD 
co-pathology (Prokopenko et al., 2019; Schaffert et al., 2020) so as is yet there is no definitive 








Figure 6: Possible molecular mechanisms of DLB. α-synuclein forms monomers (red spiral) that aggregate into 
oligomers (single red sphere). Oligomers assemble into fibrils (aggregates of red spheres). The process leads to 
cellular dysfunction and synaptic dysfunction (red crosses), cell death and neurodegeneration but the exact 
mechanisms are unknown. α-synuclein can also spread from cell-to-cell like prions via an unknown mechanism 




2.3.3. DLB Genetics 
 
Despite its relatively high prevalence, the genetics of DLB is poorly characterized compared to 
AD and PD. Having siblings with DLB raises the odds of getting it to over two-fold (Nervi et 
al., 2011), which points to a genetic etiology. However, reports of familial DLB are rare and the 
clinical manifestations vary within and between DLB families, and usually the pathological 
mutation cannot be ascertained (Anderson et al., 2006; Clarimon et al., 2009; Galvin et al., 
2002; Meeus et al., 2010; Tsuang, D. W. et al., 2002). Mutations identified in familial DLB 
overlap with AD and PD mutations and include e.g. SNCA duplication (Obi et al., 2008), APP 




al., 2004) and PSEN2 missense mutation (Piscopo et al., 2008). However, it is important to 
note that most genetic studies on familial DLB were done prior to routine WGS and advances 
in bioinformatics that have greatly improved the discovery of causal variants.  
Indeed, in recent years and with newer sequencing technologies significant progress has been 
made in unravelling the genetics of DLB. One of the first GWAS of neocortical LRP was 
conducted in Finland in the Vantaa85+ study and identified two putative loci: SPTBN1 and 
HLA-DPB1 (Peuralinna et al., 2015). The locus near SPTBN1 was replicated in a British 
sample. SPTBN1 is of special interest since it encodes a form of β-spectrin that is expressed in 
the CNS and has also been found in Lewy bodies and interacts with α-synuclein (Lee, H. J., 
Lee, & Im, 2012; Leverenz et al., 2007). 
To date, the largest GWAS of DLB consisted of 1743 cases (1324 pathologically confirmed) and 
4454 controls (Guerreiro et al., 2018). In this two-stage study, significant associations were 
found in APOE, SNCA, BCL7C/STX1B, GABRB3 and GBA. Associations with APOE, SNCA, 
and GBA were also replicated in the second stage of the study. This GWAS was a landmark 
study in DLB genetics, but at the same time it reflects how far behind DLB genetics is 
compared to AD and PD research whose largest GWASes have had 26035 to 94437 cases 
(Chang et al., 2017; Kunkle et al., 2019). 
Besides GWAS on common variants, newer studies have also studied the effects of rare 
variants on DLB. In one, GBA was also confirmed in a gene-based burden analysis studying 
rare variants (Guerreiro et al., 2018). Rare copy number variants have also been associated 
with DLB. Whole-genome genotyping of 1454 DLB cases and 1525 controls showed deletions 
in SPAG9, LAPTM4B, and NME1 loci associated with DLB. Other identified loci with 
significant associations were MSR1, PDZD2 and ADGRG. Copy number variations in SNCA 
were also identified (Kun-Rodrigues et al., 2019) in some individuals with DLB. 
Despite only a few loci associated with DLB, the phenotypic variance or heritability of DLB 
was recently estimated to be nearly 60% (Guerreiro et al., 2019) which is roughly the same as 
that estimated for AD (58% - 79%) (Gatz et al., 2006) and PD (up to 70%) (Nalls et al., 2019). 
Rare variants explained most of the heritability. Another interesting finding of the same study 
was that AD and PD polygenic risk scores were significantly associated with DLB but 
explained only a little of the phenotypic variance (1.33% and 0.37% respectively) despite the 
three best-replicated risk loci of DLB also being major risk loci for AD (APOE) and PD (GBA, 
SNCA). These observations suggest that many loci associated with DLB are yet to be found 
and require larger studies. Moreover, despite overlap in clinical features and the identification 
of AD and PD loci in GWAS, it seems that DLB is not simply an amalgamation of AD and PD 







2.3.4. Diagnosis and management 
 
Diagnosis of DLB can be challenging because of clinical overlap with other neurodegenerative 
diseases. The DLB consortium published its fourth consensus report on diagnosis and 
management of DLB in 2017 (McKeith, I. G. et al., 2017).  
The diagnosis of DLB requires many approaches. It has been demonstrated that REM sleep 
behavior disorder (RBD) often precedes other symptoms and that three fourths of autopsy-
confirmed DLB patients had RBD (Ferman et al., 2011). However, in a clinical setting, there is 
rarely any polysomnogram data and signs of RBD must be gathered from patient history and 
descriptions from their partner. Other core clinical features are dementia with fluctuations in 
cognition, visual hallucinations and parkinsonian features. Visual hallucinations are complex 
and quite vivid and relate for example to people, animals and landscapes (Harding, Broe, & 
Halliday, 2002). 
Imaging studies help diagnosing DLB, but the usefulness of routine MRI/CT is limited. In 
MRI/CT, patients with DLB usually have less atrophy in the medial temporal lobe than 
patients with AD but the sensitivity and specificity for distinguishing AD and DLB are both 
less than 70% (Harper et al., 2016). AD and DLB can be better distinguished with SPECT or 
PET where DLB has reduced DAT uptake (McKeith, I. et al., 2007). However, in patients with 
dementia and previous RBD, probable DLB diagnosis is possible if the polysomnography 
shows REM sleep without atonia (Boeve et al., 2013; McKeith, I. G. et al., 2017). Another 
promising biomarker with similar sensitivity is the low uptake of 123I-MIBG in myocardial 
scintigraphy. 123I-MIBG is similar to norepinephrine and correlates with sympathetic nerve 
denervation which is seen in PD and DLB (Komatsu et al., 2018).  
Despite recent advances in DLB genetics, there are no reliable genetic biomarkers. As yet, 
fluid biomarkers unique for DLB do not exist either. Cerebrospinal fluid (CSF) biomarkers of 
tau-pathology and Aβ are established in AD diagnostics. The same markers have been 
reported to associate with DLB in a small study (Irwin et al., 2018). However, the associations 
seem to largely stem from concomitant AD-pathology, albeit Aβ-42 levels were slightly lower 
also in DLB with low AD co-pathology compared to controls. This difference might be 
attributed to two outliers that had a large impact on the mean Aβ-42 level as the group 
consisted of only 14 individuals. 
A diagnosis of DLB is probable when there are at least two core clinical features or one core 
clinical feature with at least one biomarker and dementia begins before or at the same as 
parkinsonism (Yamada et al., 2019). The diagnostic criteria are summarized in Table 2. 
Neuropathological examination still represents the golden standard in DLB diagnostics. In 
neuropathological assessment, LRP can be divided into five categories: diffuse neocortical, 
limbic, brainstem-predominant, amygdala-predominant, olfactory bulb only, which together 
with the National Institute on Aging – Alzheimer‘s Association guidelines (NIA-AA) assess the 




been performed to assess if the LRP category affects the clinical picture have been conducted. 
Besides LRP, AD co-pathology is present in 50-80% of DLB cases (Robinson et al., 2018). 
 
 
Table 2: The diagnostic criteria of DLB according to the DLB consortium. The criteria are divided into main 
criteria and supportive criteria. 
Core clinical features 
1. Fluctuating cognition 
2. Recurrent visual hallucinations (complex and well-formed) 
3. REM sleep behavior disorder 




1. Reduced dopamine transporter uptake in basal ganglia seen in 
SPECT/PET 
2. Low uptake of 123I-MIBG in myocardial scintigraphy 




                                                           AND 
1. ≥2 core clinical features with/without indicative biomarkers 
                                                OR 
2. 1 core clinical feature + ≥1 indicative biomarker(s) 
 
 
There is no cure for DLB with the effects of current treatments limited and affecting 
symptoms and not disease advancement per se. Exercise and cognitive training are thought to 
be beneficial and can improve quality of life. No DLB-specific drugs are in routine use, rather, 
there is overlap in the pharmacological treatment of DLB, AD and PD. Cholinesterase 
inhibitors (donepezil and rivastigmine) are the first-line of drugs (Taylor et al., 2019) for both 
cognitive and psychiatric symptoms. Memantine can alleviate cognitive symptoms and 
parkinsonism may respond to careful treatment with levodopa. The use of antipsychotics and 
antidepressants for neuropsychiatric symptoms should only be used after individual 







2.4 Amyotrophic lateral sclerosis 
 
2.4.1. Definition and epidemiology 
 
ALS is a neurodegenerative disease where the upper and lower motor neurons in the brain 
and spinal cord gradually die causing the loss of voluntary movements, which eventually leads 
to respiratory failure. In ALS with FTLD, neurons also in the frontal and temporal lobes are 
affected. Up to a half of ALS patients develop at least mild cognitive or psychiatric symptoms 
and more than one in ten fulfills the criteria for the behavioral variant of frontotemporal 
dementia (Crockford et al., 2018; Phukan et al., 2012). Despite their clinical differences, ALS 
and FTLD share many common pathologic and genetic features. 
ALS is a relatively rare disease, its median prevalence has been estimated to be 5.4 per 
100 000 in Europe, 3.4 in North America, 2.01 in China and the highest in Japan with 
prevalence of 11.4 per 100 000 (Chio et al., 2013). In 1976-81 the prevalence was 6.4 in 
Middle-Finland (Murros & Fogelholm, 1983) but there are no more recent studies. Based on 
the annual incidence of ca. 150-200 cases, median survival of three years and the proportion 
of 5-10% of cases with slowly progressive disease, the number of ALS patients in Finland is 
estimated to be 400-700 (Hannu Laaksovirta, personal communication) placing Finland in 
the upper category of ALS prevalence. The incidence of ALS is greatest in the age group of 60-
75 years, but familial ALS especially can begin considerably earlier.  
Approximately 5-10% of ALS is familial (fALS) (Byrne et al., 2011) and caused by a pathogenic 
variant, most often the hexanucleotide repeat expansion in C9orf72 or in the SOD1 gene 
(Andersen, 2006; DeJesus-Hernandez et al., 2011; Renton et al., 2011). The mechanisms 
behind sporadic ALS (sALS) are more complex and environmental factors are suspected to 
play a role as well (Ingre, Roos, Piehl, Kamel, & Fang, 2015), thus the cause of the disease 
often remains unknown. ALS has been modelled to be a multistep process and these steps can 
be genetic or environmental (Al-Chalabi et al., 2014). Many environmental factors have been 
proposed to increase the risk of ALS but only smoking has proven consistent as a risk factor 
for ALS (Armon, 2009). A recent Mendelian randomization study also suggested 
hyperlipidemia as a risk factor for ALS and light physical activity as a protective factor 
(Bandres-Ciga et al., 2019). Immune system dysfunction is also suspected in ALS, supported 
by observations that autoimmune diseases such as asthma, celiac disease and systemic lupus 
erythematosus are more common in ALS patients than in the general population (Turner, 
Goldacre, Ramagopalan, Talbot, & Goldacre, 2013). 
 
2.4.2. Classification and clinical picture 
 
ALS can start focally with any voluntary muscle, so early clinical pictures vary and clinical 
diagnosis can be challenging. Diagnosis is based on clinical symptoms, 




peripheral neuropathy, radiculopathy, borreliosis, vitamin B12 deficiency, thyroid 
dysfunction, and toxic exposures, upper motor neuron diseases (HSP, PLS) and spinal 
muscular atrophy subtypes. MRI is often used but its primary function is to rule out other 
potential causes since in less than half of ALS cases brain MRI shows abnormal signals at the 
corticospinal tract and results correlate poorly with clinical data (Hecht et al., 2001). 
To effectively summarize the possible clinical pictures, ALS is often grouped by different 
criteria. First, ALS can be sporadic or familial. This dichotomy seems simple enough, but e.g. 
SOD1 mutations can have reduced penetrance and within the same family with the same 
mutation, the clinical picture and age of disease-onset can vary greatly (Rezania et al., 2003).  
Another classification that is often used is the clinical presentation at the time of diagnosis 
(spinal onset - bulbar onset – limb-onset, symmetric - asymmetric) (Al-Chalabi et al., 2016). 
In as heterogeneous a disease as ALS, classification of patients is important for several 
reasons. First, there is a need for clear criteria of clinical diagnoses so that patients are treated 
appropriately and that the relevant and right counseling for likely disease progression can be 
given. Second, different clinical pictures can represent different subtypes of the disease that 
might respond differently to treatments. Third, different information is useful in clinical trials 
where stratification with e.g. genotype information can change results. This is especially true 
for the current gene-based clinical trials emerging in ALS (clinicaltrials.gov, identifiers 
NCT04220021 (C9orf72) and NCT02623699 (SOD1)). 
 
2.4.3 ALS genetics 
 
The first ALS gene, SOD1, was discovered in 1993 (Rosen et al., 1993). SOD1 encodes the 
superoxidase dismutase 1 protein that functions against oxidative stress. Dozens of mutations 
in SOD1 have been reported and no one key pathological mechanism has been found, 
although the major mechanism is thought to be accumulation of misfolded proteins 
(Andersen, 2006). SOD1 ALS differs from other types of ALS in that it lacks TDP-43 or FUS 
pathology (Renton, Chio, & Traynor, 2014). Even though mutations are in the same gene, 
there is marked variability between patients with different SOD1 mutations. For example, 
SOD1 p.A4V, which is the most common SOD1 mutation in the USA, leads to a rapidly 
progressing form of ALS that usually results in death within a year or two of symptom onset 
(Marangi & Traynor, 2015). However, the SOD1 p.D91A (formerly denoted D90A) mutation 
that is the most common SOD1 mutation in Finland and Scandinavia, causes a slowly 
progressive form of ALS mostly in people homozygous for the mutation. The clinical picture is 
usually well recognizable and starts with a stiffness in the lower limbs that turns into paresis 
that progresses over many years (Andersen, 2006). 
To date more than 30 genes have been associated with ALS (Maurel et al., 2018). In Caucasian 
populations they explain roughly 70% of familial and 15% of sporadic cases (Chia, Chio, & 
Traynor, 2018) (Figure 7). A major breakthrough in ALS genetics came in 2011 when the 
C9orf72 hexanucleotide (GGGGCC) repeat expansion was identified (DeJesus-Hernandez et 




locus (Laaksovirta et al., 2010) with ALS. The C9orf72 hexanucleotide repeat expansion is the 
most common cause of both sporadic and familial ALS in European populations (Majounie et 
al., 2012). In an analysis of European cases, 8% of sporadic ALS and 40% of familial ALS were 
caused by the C9orf72 hexanucleotide repeat expansion. Finland is among the countries with 
the highest C9rof72 expansion frequencies and here 21.1% of sporadic and 46% of familial 














Figure 7: Percentage of familial ALS (fALS) and sporadic ALS (sALS) explained by genetics in Caucasian 
population (Chia et al., 2018). For most fALS cases, a causative genetic variant can be detected. The opposite is 
true for sALS demonstrating its complexity as a disease. In Finland, ~ 21% of sporadic and ~46% of familial ALS 





The identification of C9orf72 GGGGCC hexanucleotide repeat expansion as a cause of ALS 
was challenging as it could not easily be captured by routine variant-calling software and was 
hard to identify from aligned sequences (Figure 8). Its identification was a hallmark in ALS 
genetics since it was revealed to be the most common genetic cause of ALS in populations of 
European descent and also highlighted the importance of RNA metabolism in ALS. After its 
association with ALS and FTLD was found, there were many studies investigating whether the 
C9orf72 expansion also caused other neurodegenerative diseases. There have been several 




be mixed (Liu, Y., Yu, Zong, Zhou, & Tan, 2014) and confounded by the potential 
misdiagnosis of AD in FTLD cases and issues with statistical power. However, it seems quite 
certain that the expansion is not a major cause of AD since in AD studies, its prevalence was 
less than 1% (Kohli et al., 2013a; Majounie et al., 2012) and the C9orf72 locus has not been 
detected in the large AD GWASes (Jansen et al., 2019; Kunkle et al., 2019). The association of 
PD with the expansions has also been studied since parkinsonism is seen in up to a third of 
FTLD patients (Liu, Y. et al., 2014). The results were largely the same as in AD: it was 
reviewed that individual studies identified the expansion in less than 1% of PD but in the 
majority of studies, no expansion carriers in PD were found (Bourinaris & Houlden, 2018). 
Again, the number of cases in studies with no expansions identified were typically under a few 
hundred. Nevertheless, the expansion is not a common cause of PD. 
It is still an open question as to what repeat length is pathogenic and classifiable as an 
expansion. In the original article, repeat length of 30 was used (Renton et al., 2011) as the 
expansion threshold. It is important to note, that this threshold was selected based on 
methodological limitations rather than any biological criteria. To date, there is no consensus 
on pathogenic repeat length, so the original threshold of 30 is often still used. There have been 
studies examining the effect of “intermediate” repeat lengths on both ALS/FTLD and other 
neurodegenerative diseases. This effort is complicated by the fact that like with expansion, 
there is no standard length for “intermediate” allele length. Often ≥7 repeats is the threshold 
for intermediate repeats since those repeat lengths associate with the same haplotype as 
expansions (van der Zee et al., 2013). It was recently reviewed that intermediate repeats do 
not predispose to a variety of neurodegenerative diseases but might contribute to psychiatric 
symptoms (Ng & Tan, 2017). Subsequently, new studies observing significant effects of 
intermediate alleles have been published. A new meta-analysis that supplemented a previous 
meta-analysis (Chen et al., 2016) with a British/Alzheimer’s Disease Neuroimaging Initiative 
dataset had a total of 5071 cases and 3747 controls and found an association between ALS and 
intermediate C9orf72 repeats of 24-30 repeats (OR=4.20, p=0.02 random-effects test) 
(Iacoangeli et al., 2019). Another recently published study observed that intermediate length 
alleles of ≥ 17 repeats associated with corticobasal degeneration. They then proceeded to in 
vitro studies and showed that these alleles increased C9orf72 expression in human brain and 
in neural progenitor cells (Cali et al., 2019). 
Despite having been relatively recently discovered, major progress in understanding the 
pathological mechanisms of C9orf72 expansions has been made. Three main mechanisms 
have been identified: 1. loss-of-function of C9orf72, 2. toxic gain-of-function due to repeat 
RNA (sense and antisense) and 3. toxic gain-of-function of dipeptide repeat proteins 






Figure 8: A. C9orf72 hexanucleotide GGGGCC repeat in a genomic context. The repeat length cannot be 
determined on routine alignment since standard alignment software cannot map repeat containing reads well. B. 
Assessing repeat length with repeat-primed PCR and capillary electrophoresis. The repeat length of Sample 1 is 




Loss-of-function toxicity could be due to deficits in several cellular trafficking pathways that 
include inhibited autophagy, reduced endocytosis and impaired lysosomal function. C9orf72 
knock-out cells are also susceptible to excitotoxicity due to surplus glutamate receptors 
(Selvaraj et al., 2018). The function of C9orf72 in immune regulation also seems to be 
important (Balendra & Isaacs, 2018). Importantly, C9orf72 knock-out mice do not develop 
motor neuron degeneration suggesting that loss-of-function of C9orf72 is probably not a 
major component of pathogenic mechanisms. However, the knock-out mice develop a fatal 
autoimmune disease that has some similarities to systemic lupus erythematosus (Burberry et 
al., 2016). A recent study on mice with loss of C9orf72 from myeloid cells alone caused the 
same autoinflammatory phenotype and it was linked to impaired degradation in the 
stimulator of interferon genes (STING) protein via the autolysosomal pathway (McCauley et 
al., 2020). STING has been reviewed to be an important inducer of autoimmune diseases 
including systemic lupus erythematosus (Kumar, 2019). The C9orf72 knock-out myeloid cells’ 
oversensitivity to STING can explain the surplus of autoimmune diseases in ALS patients 
(Turner et al., 2013). 
Toxic gain-of-function mechanisms include RNA secondary structures such as G-
quadruplexes that lead to abnormal binding and depletion of many RNA-binding proteins 
(DeJesus-Hernandez et al., 2011; Donnelly et al., 2013). RNA-binding proteins are important 
in RNA regulation and act in splicing, degradation and transport of RNA. The role of 
dipeptide repeat proteins is more unclear since in post-mortem studies dipeptide repeat 
proteins do not overlap well with TDP-43 pathology and are present in CNS regions not 
affected by ALS/FTLD. Nevertheless, dipeptide repeat proteins may be important in earlier 
stages of disease and there is evidence of its neurotoxicity in disease models (Balendra & 
Isaacs, 2018). Furthermore, the accumulation of dipeptide repeat proteins may have a 
synergetic effect with the loss-of-function of C9orf72 that inhibits autophagy and the 






Figure 9. Key molecular mechanisms of the C9orf72 hexanucleotide repeat expansion. 
 
 
2.4.5. Molecular mechanisms and neuropathologic features 
 
The molecular mechanisms behind ALS vary with the underlying cause but the common 
pathway is aggregation of ubiquitinated proteins that can be seen as cytoplasmic inclusions in 
motor neurons but also in cerebellar cells in the CNS (Al-Chalabi et al., 2012). TAR DNA-
binding protein 43 (TDP-43) is a major component of these inclusions (Arai et al., 2006; 
Neumann et al., 2006). Even in patients with no TARDBP mutations, TDP-43 is present in the 
vast majority of SOD1-negative ALS patients and pathological inclusions positive for TDP-43-
immunohistochemistry are seen in motor neurons of the anterior columns of the spinal cord 
the neurons of hypoglossal nuclei, and possibly in neurons of the primary motor cortex, 
hippocampus and frontal cortex. In addition, TDP-43-positive neurites are often seen in these 




TDP-43 C-terminal fragments that are prone to aggregation. In rat studies, the aggregation 
tendency of mutant TDP-43 is often greater but it seems that both mutant and wild-type TDP-
43 can be neurotoxic and increased levels is the key to its pathogenicity (Barmada et al., 
2010). In ALS patients with mutations in FUS, there are FUS-positive cytoplasmic inclusions. 
Like TDP-43, FUS is an RNA-binding protein but whether its aggregates are consistently 
present in ALS patients without FUS-mutations is unclear since both findings are reported 
(Blokhuis et al., 2013). Also, some SOD1 mutations lead to accumulation of SOD1 inclusions, 
but inclusions of misfolded wild type SOD1 have also been reported in ALS patients with 
mutations in other ALS genes than SOD1, which suggests that misfolding also of wild type 
SOD1 can be part of the pathogenic pathway (Forsberg et al., 2019). 
Similar to α-synuclein in DLB, SOD1, FUS and TDP-43 proteins have been hypothesized to 
have prion-like qualities that would allow them to spread from cell to cell. It has been 
observed especially with SOD1 that misfolded proteins seen in ALS could cause their native 
counterparts to aggregate. The hypothesis is that protein destabilizing mutations in SOD1 
(and FUS gene and C-terminal region of TARDBP) cause prion-like domains to be unfolded 
that then work as seeds for further aggregation initiating a self-perpetuating cycle 
(Polymenidou & Cleveland, 2011). In cell culture, these protein aggregates have been shown to 
spread from cell to cell even without direct contact via micropinocytosis and this transfer 
seems efficient (Munch, O'Brien, & Bertolotti, 2011). Since then, this spreading has been 
demonstrated also in vivo in mice where the injection of mutant SOD1 protein into the sciatic 
nerve triggered a spreading motor neuron disease (Ayers, Fromholt, O'Neal, Diamond, & 
Borchelt, 2016).  
Other pathological mechanisms suggested in ALS include oxidative stress, mitochondrial 
dysfunction, axonal damage, excitotoxicity and neuroinflammation. The role of oxidative 
stress is highlighted by the normal function of SOD1: it has been reviewed to clear reactive 
oxygen species, molecules that can damage e.g. DNA, proteins and lipids (Tarafdar & Pula, 
2018). Mitochondria are the prime location of energy production in cells. In mitochondria, 
oxidative phosphorylation creates ATP but also reactive oxygen species as a by-product. Thus, 
mitochondria are prone to oxidative damage especially when there is additional cell stress. 
Coupled with neurons’ high metabolism and resulting oxygen use, neurons are regarded to be 
highly susceptible to oxidative stress and oxidative damage (Singh, Kukreti, Saso, & Kukreti, 
2019). Therefore, it is no surprise that oxidative stress is associated with several 
neurodegenerative diseases like AD and PD, and not just ALS. In ALS, excess reactive oxygen 
species and resulting damaged molecules have been found in blood, urine and cerebrospinal 
fluid (Liu, J. & Wang, 2017). 
Excitotoxicity is a phenomenon where nerve cells are damaged and die due to overactivation 
of receptors of excitatory amino acids (most often glutamate) which leads to an influx of ions, 
particularly calcium (Dong, Wang, & Qin, 2009). The C9orf72 hexanucleotide repeat 
containing RNA has been shown to bind the glutamate receptor (GluR2) sequestering enzyme 
ADARB2 and thus preventing normal editing of the receptor pre-mRNA (Donnelly et al., 
2013). This in turn leads to sensitivity for glutamate excitotoxicity in cultured iPS-neurons 




by abnormal glutamate metabolism in ALS (Plaitakis & Caroscio, 1987) and the (albeit 
modest) effect of riluzole that modulates the glutamatergic system in ALS (Bensimon, 
Lacomblez, & Meininger, 1994).  
In addition to motor neurons, glial cells may also affect the pathogenesis of ALS. Microglial 
activation is seen in ALS and microglia are viewed to have an important role in maintaining a 
suitable environment for nerve cells via e.g. uptake of misfolded proteins (Liu, J. & Wang, 
2017). The role of astrocytes in the pathogenesis of ALS has also been recently studied. It has 
been reported that astrocytes from both fALS and sALS patients are toxic to motor neurons 
(Haidet-Phillips et al., 2011). Interestingly, astrocytes differentiated from fibroblasts of a sALS 
patient, an ALS patient with C9orf72 hexanucleotide expansion, and an ALS patient with 
SOD1 A4V mutation were all toxic toward motor neurons (Meyer et al., 2014). This 
observation suggests that changes in astrocyte function may be a common mechanism in ALS. 
The potential role of glial cells in the pathogenesis of ALS highlights the importance of 




At the moment, riluzole is the most widely used drug for ALS and prolongs survival, albeit on 
average by only three months (Bensimon et al., 1994). Patients generally survive only 2-5 
years after diagnosis (Miller, Mitchell, & Moore, 2012). Even though present treatment 
options are scarce and have a limited effect, increasing understanding of genetic and 
pathological mechanisms behind ALS promises treatments that are more effective. At the 
moment, there are dozens of ongoing clinical trials (https://clinicaltrials.gov/, accessed 
14.7.2020) and encouraging results from antisense oligonucleotide (ASO) therapies have 
raised interest as a future treatment (Klim, Vance, & Scotter, 2019). ASOs are a versatile tool: 
they bind to mRNA in the nucleus and can promote its cleaving, effectively silencing a gene. 
They can also inhibit translation in ribosomes or alter splicing. Nusinersen, a drug for spinal 
muscular atrophy, increases SMN1 expression by converting SMN2 mRNA into SMN1-like 
mRNA. Albeit effective (Finkel et al., 2017), the very high price of Nusinersen (and most likely 
future ASOs) restricts its use and has sparked major debate on whether the drug is given and 










2.5. Alzheimer’s disease 
 
2.5.1. Definition and epidemiology 
 
AD is the most common cause of dementia (Ince et al., 1995) and arguably the best-known 
neurodegenerative disease in the general population. Its hallmark is progressive loss of 
memory. AD can be familial (early-onset) or sporadic (late-onset). The prevalence of AD is 
affected by age and whether clinical or neuropathological diagnosis is used. In different 
autopsy series focusing on patients with dementia, the frequency of AD ranged from 64% to 
90% (Barker et al., 2002). In a population-based study of individuals over 75 years in the 
Kuopio region in Finland, the prevalence of AD was 10.6%, which accounted for 47% of all 
demented individuals (Rahkonen et al., 2003). However, the main neuropathological changes 
associated with AD, neuritic plaques and neurofibrillary tangles (NFTs), are even more 
prevalent than the actual disease. Even in individuals with generally minimal 
neuropathological changes, there were neuritic plaques in 50% and tau pathology in 93% of 
cases (mean age 70) (Robinson et al., 2018).  
 
2.5.2. Clinical picture 
 
The stage of AD defines its clinical picture. In early-stage (mild) AD, memory loss and other 
cognitive dysfunctions are not yet necessarily evident and can include difficulties in 
remembering recently read material or misplacing objects. In the middle-stage (moderate) 
AD, patients require external help in their daily lives. Symptoms include evident forgetfulness, 
confusion, and behavioral changes. In the late-stage (severe) AD, patients require continuous 
assistance, awareness of surroundings is lost, communication becomes difficult and physical 
abilities greatly weaken. 
Probable AD dementia is diagnosed clinically when there is dementia and 1. the onset was 
gradual over months to years, 2. the cognitive functions have clearly worsened over time and 
3. the initial and most prominent deficits are amnestic (especially impairment in learning and 
recall of recently learned information) with dysfunction in other non-amnestic cognitive 
processes such as impaired executive dysfunction, impaired visuospatial abilities, impaired 
language functions or changes in personality or behavior. The most prominent deficit in AD 
can also be non-amnestic but in those cases there should also be deficits in other cognitive 
domains (McKhann et al., 2011). The golden standard of AD diagnosis is neuropathological 
examination. The likelihood of AD is high if there are frequent neuritic plaques in the 
neocortex according to the Consortium to Establish a Registry for Alzheimer Disease 






2.5.3. AD genetics 
 
The genetics of AD vary between familial and sporadic forms. In familial AD, the disease onset 
is usually before 65 years and there is a pathogenic mutation in APP (Goate et al., 1991) on 
chromosome 21, in PSEN1 (Sherrington et al., 1995) in chromosome 14 or in PSEN2 (Levy-
Lahad et al., 1995) on chromosome 1. All three of these genes are involved in Aβ metabolism. 
APP encodes amyloid precursor protein and PSEN1 and PSEN2 encode presenilins 1 and 2, 
which regulate APP processing via the γ-secretase enzyme. A recent review counted over 50 
APP mutations, more than 30 in PSEN2 and more than 200 in PSEN1 that have been 
identified in AD but together they explain only ca. 10% of familial AD cases (Cacace, Sleegers, 
& Van Broeckhoven, 2016).  
The sporadic or late-onset AD is a complex disease and has many genetic risk factors. APOE 
ε4 is the most common genetic risk factor (Strittmatter et al., 1993). Its mean frequency in 
populations under 65 years is ca. 15% (Eisenberg, Kuzawa, & Hayes, 2010) and it has an odds 
ratio of 3-15 depending on the number of copies carried (Amouyel, Brousseau, Fruchart, & 
Dallongeville, 1993).  
In recent years, two exceptionally large meta-analysis GWASes on AD have been published 
with tens of thousands of cases and controls (Jansen et al., 2019; Kunkle et al., 2019). In both, 
the APOE locus was the strongest association signal. Besides APOE, the studies reported 20 
(Kunkle et al., 2019) and 28 (Jansen et al., 2019) loci with genome-wide significant 
associations (Table 3). These loci largely overlap with those reported in previous GWASes but 
some previously reported loci did not reach genome-wide significance. Variants in the genes 
ABCG1, GALNT7, MEF2C, NME8, GAB2, EXOC3L2, TRIP4 and an intergenic region in 
chromosome 9 were not replicated in these two large meta-analysis GWASes by Beecham et. 













Table 3.  Loci with genome-wide significant associations in AD in two recent large meta-analysis GWAS projects. 
Chromosome Gene/Locus Reported by Jansen 
et al. 
Reported by Kunkle 
et al. 
1 ADAMTS4 X 
 
1 CR1 X X 
2 BIN1 X X 
2 INPPD5 X X 
3 HESX1 X 
 
4 CLNK X 
 
6 HLA-DRB1 X X 
6 TREM2 X X 
6 CD2AP X X 
7 ZCWPW1 X X (NYAP1) 
7 EPHA1 X X 
7 CNTNAP2 X 
 
8 CLU/PTK2B X X 





11 MS4A locus X X 
11 PICALM X X 




15 ADAM10 X 
 
15 APH1B X 
 
16 KAT8 X 
 
17 SCIMP X 
 





18 ALPK2 X 
 
19 ABCA7 X X 
19 APOE X X 
19 AC074212.3 X 
 
19 CD33 X X 
20 CASS4 X X 
 
 
2.5.4. Molecular mechanisms and neuropathology 
 
AD can be thought to develop through two stages. First is a preclinical stage with 
neuropathological changes but no apparent cognitive symptoms (Price & Morris, 1999). In the 




neuropathological changes progress to mild cognitive impairment and not all who have mild 
cognitive impairment develop dementia (Petersen et al., 1995; Varatharajah, Ramanan, Iyer, 
Vemuri, & Alzheimer's Disease Neuroimaging Initiative, 2019). 
In the preclinical stage, there are neuritic plaques (extracellular Aβ accumulations) and NFTs 
in the entorhinal cortex and hippocampus CA1 region and there is none to little cell loss in 
these regions. In comparison, in “normal” aging there are fewer neuritic plaques, and 
entorhinal and hippocampal regions have fewer NFTs and there is no cell loss (Price, Davis, 
Morris, & White, 1991; Price & Morris, 1999). Modern imaging technologies includindg high 
PET amyloid tracer retention and cortical thinning/hippocampal atrophy on structural MRI 
with CSF Aβ and tau markers have been proposed as biomarkers for preclinical AD in 
research use (Sperling et al., 2011). 
According to NIA-RI criteria, the neuropathological diagnosis of AD requires that there is 
frequent and widespread neuritic plaques and NFTs (Consensus recommendations for the 
postmortem diagnosis of alzheimer's disease. the national institute on aging, and reagan 
institute working group on diagnostic criteria for the neuropathological assessment of 
alzheimer's disease.1997). The NIA-RI criteria are based on two classification schemes: 
CERAD (Mirra et al., 1991b) and Braak stage (Braak, Alafuzoff, Arzberger, Kretzschmar, & Del 
Tredici, 2006; Braak & Braak, 1995). CERAD focuses on the frequency of neuritic plaques 
whereas Braak staging focuses on NFTs. 
The neuropathological criteria for AD highlight the importance of neuritic plaques and NFTs 
in AD. The main component of NFTs is hyperphosphorylated tau that aggregates into fibrils. 
Tau normally associates with microtubules (Witman, Cleveland, Weingarten, & Kirschner, 
1976) but its phosphorylation induces its release from microtubules, which allows it to 
aggregate (Biernat et al., 1992). According to NFT Braak staging in AD, NFTs first appear in 
the transentorhinal and the entorhinal regions (stages 1 and 2), then proceed to the limbic 
regions including hippocampus CA-1 (stage III). From there, NFTs become more widespread 
until at last (stage VI), there is widespread neocortical NFT pathology (Braak & Braak, 1995). 
The other pathological hallmark of AD is neuritic plaques whose main component is Aβ. 
Different Aβ peptides are cleaved by β and γ-secretases from APP. Neuritic plaques are 
extracellular aggregations of amyloid fibrils (Glenner & Wong, 1984) but Aβ is not only 
observed as parenchymal deposits in AD. It is also present as cerebrovascular changes (in 
small arterioles and capillaries) in cerebral amyloid angiopathy (CAA) (Pantelakis, 1954). CAA 
is not specific to AD and is observed in 20-60% of non-demented individuals, in 50-80% of 
demented individuals and in approximately 90% of AD patients (Arvanitakis et al., 2011; 
Keage et al., 2009; Mandybur, 1975). CAA can be divided into two types. In type 1, there is Aβ 
in at least cortical capillaries and in type 2 there are amyloid deposits in cortical and 
leptomeningeal arteries but not in capillaries (Attems, Jellinger, Thal, & Van Nostrand, 2011; 
Attems, Yamaguchi, Saido, & Thal, 2010).  
The Aβ cascade is a key pathway in the development of familial AD as demonstrated by the 
three genes (APP, PSEN1, PSEN2) whose mutations lead to familial AD. In sporadic AD, Aβ 
processing is regarded as an important pathway, but other factors are crucial as well. APOE is 




especially in innate immune cells and brain microglia (Huebbe & Rimbach, 2017; Krasemann 
et al., 2017). Another important gene that highlights the importance of immune responses in 
AD is TREM2. The rare (MAF 0.25% in Europe) R47H substitution has an effect size 
comparable to APOE ε4 (Jonsson et al., 2013). The two new large GWASes strengthen the 
importance of immunological pathways as e.g. HLA-DRB1, CR1 and CD33 were associated 
with AD in both studies. Variants in MAPT, the gene that encodes tau, have not associated 
with AD in the recent GWASes but tau binding proteins were implicated in pathway analyses. 
In other studies, the H2 MAPT haplotype has been associated with a reduced risk of AD (Allen 
et al., 2014) (Figure 10). 
 
 
Figure 10. Main molecular pathways of late-onset AD and examples of genes in pathways. Different cellular 
processes lead to neurodegeneration and visible loss of brain tissue. Genetic variations in one gene can play a 









There is no disease-modifying treatment for AD. The prominence of Aβ pathology in AD and 
the amyloid cascade hypothesis as the primary mechanism behind AD has led to large efforts 
in immunotherapies targeting the amyloid protein. However, to date no clinical trial has been 
successful either due to lack of effect or severe side effects. 
The most used pharmacological treatments include cholinesterase inhibitors and memantine. 
Cholinesterase inhibitors ease symptoms in early and mid-phases of AD leading to better 
cognitive function and improved quality of life (Rogers & Friedhoff, 1996). In AD, cholinergic 
neurons and neural circuits deteriorate (Bartus, Dean, Beer, & Lippa, 1982). Cholinesterase 
inhibitors increase acetylcholine concentration, which improves neurotransmission and 
alleviates symptoms.  
Memantine is another widely used drug for AD, albeit it seems to alleviate symptoms in only 
moderate to severe AD (Schneider, Dagerman, Higgins, & McShane, 2011). Memantine blocks 
NMDA receptors (glutamate receptors) and decreases excitotoxicity (Kornhuber, Weller, 





















3. AIMS OF THE STUDY 
 
The general aim of this study was to investigate different genetic variations behind ALS, AD 
and DLB. 
The specific aims were: 
1. Publication I: To study if C9orf72 hexanucleotide repeat intermediate length alleles are 
a risk factor for AD or cognitive impairment. The second objective was to describe the 
C9orf72 allele length distribution in an older Finnish population to assess the 
pathogenic repeat length. 
 
2. Publication II: To genotype a large number of Finnish individuals with ALS and 
controls in order to study the potential effects of C9orf72 hexanucleotide intermediate 
alleles on ALS and their clinical relevancy. 
 
3. Publication III: To study the distribution of LRP in the central nervous system in an 
aged population-based cohort and its association with AD pathology. 
 
4. Publication IV: To study how the previously reported AD risk loci associate with the 
different neuropathological features of AD (CERAD score, Braak staging, cerebral 















4. MATERIALS AND METHODS 
 
4.1. Study cohorts 
 
4.1.1. Vantaa85+ study 
 
The Vantaa 85+ Study consists of individuals of at least 85 years of age, who were living in the 
city of Vantaa, Finland on April 1st 1991. Professor Raimo Sulkava and chief physician Leena 
Niinistö initiated the study. There were 601 eligible individuals and of them, 553 participants 
underwent neurological examination including MMSE by two neurologists in 1991–1992, with 
follow-up studies in 1994, 1996, 1999, and 2001. Neuropathological autopsy was performed 
on 306 individuals.  
Neuropathological examinations included assessment of α-synuclein with 
immunohistochemistry using a mouse monoclonal anti-α-synuclein antibody (clone 5G4, 
1:1000, AJ Roboscreen GmbH, Leipzig, Germany or Merck KGaA, Darmstadt, Germany) 
(Kovacs et al., 2012). α-synuclein was assessed from 11 anatomic regions: sacral and thoracic 
spinal cord, medulla oblongata, pons, midbrain, amygdala, hippocampus from the right 
hemisphere, cingulate cortex, frontal cortex, temporal cortex and parietal cortex. This allowed 
semiquantitative scoring of LRP and the classification of individuals. 
Neuritic plaques were assessed by Bielshowsky silver stain according to CERAD protocol 
(Mirra et al., 1991a) and neurofibrillary tangles by Gallyas silver stain method according to the 
protocol by Braak and Braak (Braak & Braak, 1995) 
4.1.2. Helsinki Birth cohort study  
 
The Helsinki Birth cohort study consists of 8760 individuals born in Helsinki in 1934-1944 
(Barker et al., 2005, Eriksson et al., 2006). A random subsample of 2003 individuals 
underwent DNA extraction (Kajantie et al., 2012, Yliharsila et al., 2007) and assessment of 
cognition with MMSE and CERAD in 2001-2004. In addition, information on cognition and 
psychiatric diagnoses were available up till December 31 of 2013. These data included 
dementia hospitalizations and dementia deaths as well as psychiatric diagnoses (F00-F99 for 
ICD-10, 290-319 for ICD-9 and 290-299, 301 for ICD-8) and selected neurodegenerative 
diseases such as AD, Parkinson disease, ALS/FTLD and multiple sclerosis (G10-13, G20-26, 
G30, G35-37 for ICD-10, 331-333 and 340-341 for ICD-9, 340-341 and 348 for ICD-8) . These 







4.1.3. Helsinki Businessmen Study 
 
Helsinki Businessmen Study participants were originally 3,490 healthy Finnish businessmen 
or executives, born 1919-1934 with similar high socioeconomic status. In 2002-2003, 672 
home-living but otherwise randomly selected men were selected as a subsample and their 
cognition tested using MMSE (Strandberg et al., 2016) with 650 also giving a venous blood 
sample from which DNA was extracted. In 2014, their cognition was re-evaluated with a 
questionnaire. 
 
4.1.4. DEBATE study 
 
The DEBATE cohort is based on a random sample of 4,800 individuals who were living in 
Helsinki, Finland. The studied subsample was formed in 2000 from 400 home-living 
individuals with stable cardiovascular disease (peripheral artery disease, coronary artery 
disease, stroke or transient ischemic attack). The individuals in the subsample were clinically 
examined and their cognitive function were assessed with MMSE (Uusvaara, Pitkala, 
Kautiainen, Tilvis, & Strandberg, 2013). Additionally in 2014, dementia diagnoses were 
screened from death certificates. 
4.1.5. ALS patients 
 
The ALS cohort consisted of 773 ALS patients who were recruited at the Department of 
Neurology, Helsinki University Hospital, since 1994. The department receives referrals from 
neurologists throughout Finland. There were 177 (23%) familial ALS cases and 596 apparently 
sporadic cases. The patients’ mean age-of-onset was 58 years and 51% were females. The 
C9orf72 repeat expansion was in 25% of all ALS cases. 
 
4.1.6. PLASTICITY study 
 
The PLASTICITY study (Hokkanen, Launes, & Michelsson, 2013) is a prospective study whose 
main objective is to assess how neonatal risk factors affect neurodevelopmental and 
neurodegenerative processes. It consisted initially of 1196 people born in 1971-1974 at the 
Helsinki metropolitan area maternity hospital (Kätilöopisto) who had at least one neonatal 
risk factor (e.g. birth weight < 2000g, need of external ventilation/ischaemia or asphyxia, 
Apgar < 7, neurological symptoms). Children were clinically examined at ages of 5, 9 and 16 
and filled a questionnaire at 30. Possible ALS/FTLD diagnoses were derived from clinical 
records, medication reimbursement registry, neuropsychological examination and clinical 




4.1.7. Blood donor cohort 
 
The blood donor cohort consists of a collection of 400 healthy blood donors aged 18-65 years 
at the time of study participation, who were recruited in Northern Ostrobothnia (n=102), 
Kainuu (n=85), North Savo (n=61), Pirkanmaa (n=152) (Meinila, Finnila, & Majamaa, 2001; 
Niemi et al., 2003). 
 
4.2. Genotyping and sequencing 
 
DNA was extracted from venous blood samples (peripheral blood leukocytes) or in some 
individuals of the Vantaa85+ study from brain samples using standard methods. In the 
PLASTICITY study, DNA was extracted from saliva samples. 
 
4.2.1. Vantaa85+ genotyping, sequencing and imputation 
 
Genome-wide genotyping in 512 participants was done with the HumanCNV370 array 
(Illumina, CA, USA) according to the manufacturer’s recommendations. BeadStudio v. 3.2 
(Illumina) was used for reclustering with a no-call threshold of 0.15. Per-sample and per-
variant quality control steps were: related individuals (identity by descent >0.185), individuals 
with divergent ancestry, individuals with discordant sex information, outlying heterozygosity 
rate (±2 SD) or elevated missing data (>3%) rate, and were excluded. Variants with missing 
per person rate >10%, missing data rate >5 %, minor allele frequency <1% or significantly 
different genotype call rates between cases and controls (p < 0.00001) were excluded. 
Variants not in Hardy-Weinberg equilibrium (p < 0.00001) were also excluded. 
Whole-genome sequencing of 309 samples selected by DNA quality and quantity was done at 
Broad Institute. Samples were prepared with Illumina TruSeq DNA PCR Free library 
preparation kit and sequenced with the HiSeq X10 sequencing system to produce 150-base 
pair paired-end reads according to the manufacturer’s protocol. We processed the raw 
sequence data using GATK (McKenna et al., 2010) according to the Broad Best Practices 
application program interface. 
We performed whole-genome imputation using the HumanCNV370 array data and the 
population-specific SISu v3 imputation reference panel. First, in per-sample quality control, 
individuals with discordant sex information, excess heterozygosity (+-4SD) and high genotype 
missingness (>5%) were excluded. Then, in per-variant quality control, variants with high 
missingness (>2%), not in HWE (p<1e-6) and minor allele count < 3 were removed. The 
Vantaa85+ samples were merged with a larger dataset originating from a similar genotyping 
approach and pre-phased with Eagle 2.3.5 
(https://data.broadinstitute.org/alkesgroup/Eagle/) with the default parameters, except the 




Two sets of imputations were done in Vantaa85. First, only AD risk loci were imputed. This 
was done using IMPUTE2. 1000 Genomes phase3 data (October 2014 release) supplied by 
IMPUTE2 were used as the reference panel.  
Second, genome-wide imputation was done using the population-specific SISu v3 imputation 
reference panel with Beagle 4.1 (version 27Jan18.7e1, 
https://faculty.washington.edu/browning/beagle/b4_1.html) as described in the following 
protocol: dx.doi.org/10.17504/protocols.io.nmndc5e. High-coverage (25-30x) whole-genome 
sequence data was used to develop the SISu v3 reference panel (Pärn et al., manuscript in 
preparation). the variant callset was produced with GATK HaplotypeCaller algorithm by 
following the GATK best-practices for variant calling. Genotype-, sample- and variant-wise 
QC was applied in an iterative manner by using the Hail framework (https://github.com/hail-
is/hail) v0.1 and the resulting high-quality WGS data for 3,775 individuals were phased with 
Eagle 2.3.5 as described above. 
Post-imputation quality control consisted of discarding variants with an imputation info score 
< 0.3 and a minor allele frequency threshold of 0.01. 
 
4.2.2. APOE genotyping 
 
In all studies, APOE was genotyped with a PCR assay as previously described (Myllykangas et 
al., 1999). In brief, a PCR assay with HhAl restriction was used and the amplicons were 
visualized with agarose gel electrophoresis. Different amplicon lengths represent different 
genotypes. When possible, genotypes were double checked with genotyping or sequencing 
data. 
 
4.2.3. C9orf72 hexanucleotide repeat length assessment 
 
The C9orf72 hexanucleotide repeat length was determined with repeat-primed PCR and 
putative expansions were confirmed with over-the-repeat PCR as previously described 
(Renton et al., 2011). In brief, first repeat-primed PCR with fluorescent primers was 
performed and amplicons were then run on capillary electrophoresis. Then, putative 
expansions were verified with over-the-repeat PCR and compared to in-house control samples 
with known repeat lengths. In over-the-repeat PCR, the hexanucleotide repeat locus is 
amplified. Alleles with the expansion do not amplify since they are too long for the PCR. 








RESULTS AND DISCUSSION 
 
4.1. C9orf72 repeat lengths in aged Finnish population and association 
with cognition 
 
We characterized the repeat length of 3142 Finns from four cohorts: the Vantaa85, DEBATE, 
HBCS and HBS. The mean age was 78 years, age range was 58-101 and there were 49% 
women. The distribution of repeat lengths was largely the same between cohorts (Kruskal-
Wallis H test, H (3) = 2.129, p = 0.55) except that all expansions came from the largest cohort 
(HBCS). All expansions were confirmed with over-the-repeat PCR. 
The repeat length distribution showed peaks at 2(–3), 5, 8, and 10 repeats as previously 
described (Figure 11). The longer allele was in the range of 7–45 repeats in 1036/3142 (33%) 
individuals, 20–45 in 56/3142 (1.8%), 30–45 in 12/3142 (0.38%), and expansion (>45 




Figure 11. C9orf72 repeat length distribution in aged Finnish individuals. Exp denotes an expansion. 
 
Therefore, the allelic frequency of ≥20 repeats was 0.89% in Finland. This allelic frequency 
was found to be statistically significantly more common (all p < 0.019) than in four previous 
large (cohort studies of >1000 individuals or case-control studies with >1000 controls) 
studies where the allelic frequency was 0.38 – 0.52% (Table 4). The C9orf72 hexanucleotide 
expansion is especially common in Finland (Majounie et al., 2012) and also the higher 
prevalence of ≥20 repeats, raises the thought that the longer repeat alleles could be prone to 
germline instability and becoming large expansions in offspring. A similar mechanism has 




by assessing the repeat length of the parents of the C9orf72 expansion positive patients. 
However, reliable results would require a large number of trios to be studied and since ALS is 
often diagnosed quite late in life, the patient’s parents might no longer be alive. Potential 
mosaicism could also be a problem for interpreting the results if the repeat length was 
assessed only from blood-derived DNA. 
 
Table 4. The frequency of long intermediate-length repeats in large control or general population. 























British 1958 birth 
cohort 
7577 64 0.42 0.000051 11 (Beck et al., 
2013) 
Irish 1234 10 0.41 0.019 0 (Fahey 




5886 61 (≥17 
repeats) 
0.52 0.0045 1 (Theuns 
et al., 2014) 
North American  1444 11 0.38 0.0078 0 (Rutherford 
et al., 2012) 
 
 
We also found that intermediate repeat lengths did not associate with cognitive impairment or 
AD (all p > 0.05). This lack of association held regardless of the threshold (7 or 20) for 
intermediate repeat length.  
Moreover, contrary to the assumption of 30 repeats being pathogenic, we found 30-45 repeats 
in 0.38% (1 per 262) of individuals, and they did not have any apparent clustering of 
neurodegenerative or psychiatric diagnoses. The characterization of pathogenic threshold is 
important for several reasons. First, when counselling patients with suspected or confirmed 
ALS, it is important to known if their C9orf72 repeat length is likely to be relevant to their 
disease or if other risk factors should be sought. This is also important in clinical trials when 
patients are pooled based on their primary mutation. Second, when studying the effects of 
different repeat lengths in vitro or in vivo, it is important to know what repeat lengths are 




biological change in comparison to wild type alleles but if those intermediate-length alleles do 
not associate with disease in humans, the effect is likely not to be clinically relevant. 
Biological processes are seldom exact and the pathological threshold of repeat length can be a 
“gray zone” where disease penetrance is dependent on modulating cofactors. Statistical power 
is especially important to consider in negative result studies where a minute effect could have 
been left unseen. However, intermediate repeats are not a strong (relative risk >1.5) risk 
factor for AD or cognitive impairment. 
The C9orf72 hexanucleotide repeat expansion was discovered as late as in 2011 as a major 
cause for ALS and FTLD (DeJesus-Hernandez et al., 2011; Renton et al., 2011). Since 
neurodegenerative diseases share molecular mechanisms and several genes are known to be 
risk factors for multiple neurodegenerative diseases, it was natural that the association of 
C9orf72 hexanucleotide repeat with various other neurodegenerative diseases was quickly 
tested. The results were mixed (Ng & Tan, 2017) as spurious positive associations are quite 
common as is a lack of sufficient power required for reliable negative results. Furthermore, as 
there is population-level variability in the prevalence of both expansion and intermediate 
alleles, population stratification needs to be considered. By studying a large number of 
Finnish individuals, we were able to control for population stratification and the higher than 
average prevalence of longer intermediate repeats allowed sufficient power. A limitation of 
our study was that we could not control for all important factors that affect cognitive 
impairment. One example is that the level of education was quite heterogeneous in our 
cohorts. Furthermore, there was variability in the assessment of cognition. Nevertheless, our 
data provide good evidence on the effects of C9orf72 intermediate repeats on AD and 
cognitive impairment. 
To date, there has not been any new data published that would contradict our results. The 
current view is that the C9orf72 hexanucleotide expansion is at most a rare cause of AD (Kohli 
et al., 2013b; Majounie, Abramzon et al., 2012). Individuals clinically diagnosed with AD 
carrying the expansion may have in reality e.g. FTLD. AD can also resemble limbic-
predominant age-related TAR-DNA-binding protein-43 (TDP-43) encephalopathy (LATE-NC) 
and its association with C9orf72 has not yet been extensively studied. Nevertheless, the effects 












4.2. C9orf72 intermediate length alleles and ALS 
 
Since Publication I, new data suggesting the pathogenicity of C9orf72 intermediate repeats 
were published, e.g. the meta-analysis of 24-30 repeats and ALS (Iacoangeli et al., 2019) and 
17-30 repeats and corticobasal degeneration (Cali et al., 2019).  
To study the effects of intermediate repeats on ALS, in addition to the 3142 older Finns we 
previously genotyped, we determined the C9orf72 repeat length in 433 younger (mean age 42 
years) Finns from the PLASTICITY study, 400 individuals from the blood donor cohort and 
758 Finnish ALS patients from Southern Finland. Again, genotyping success rate was high 
(97-99%). Since the effect of an expansion most likely overshadows any effects of an 
intermediate repeat, we excluded expansion carriers from our primary analyses. After quality 
control steps, there were 525 ALS cases and 3950 controls for the main analyses. 
As discussed earlier, there is no one definitive threshold for intermediate repeat length, so we 
chose several based on the level of previous evidence. The intermediate thresholds were 7-45, 
17-45, 21-45, 24-45 and 24-30. Intermediate repeat length alleles did not associate with ALS 
(Fisher’s test all p ≥ 0.15) when the effect of the longer allele was considered (Table 5). We 
also tested if intermediate alleles had an impact on survival presenting as decline in the 
intermediate allele frequency in older age groups versus younger age groups. We distributed 
controls into three age groups (18-65, 66-84 and 85-105 years) and tested if there was a 
difference in the frequency of intermediate allele carriers. We did not observe a linear trend 
between age group and the frequency of intermediate-length allele carriers (Cochran-
Armitage trend test, all p ≥ 0.33) (Table 6) in any of the intermediate repeat length 
thresholds. 
However, there was a difference in the proportion of individuals with two intermediate-length 
alleles between ALS cases and controls (p=0.005, OR 1.93, CI=1.19-3.02). The estimated 
effect increased with the repeat length of the longer allele (Table 7). We obtained similar 
results when testing the effect of the SNP rs3849942 whose allele A tags repeat lengths of ≥7. 
There were more individuals with ALS than controls with A/A genotype (p= 0.018, OR=1.89, 
95%CI 1.20-2.99). This suggests that our intermediate-repeat assessment has been reliable 
even though samples with two intermediate-length alleles are difficult to genotype. 
Taken together, our data suggest that one intermediate allele is not a risk factor for ALS in 
Finland, but carrying two intermediate-length alleles increases the risk of ALS. Our results are 
somewhat in contrast with some earlier studies, perhaps most notably the large meta-analysis 
of 5071 ALS cases and 3747 controls discussed earlier (Iacoangeli et al., 2019). However, this 
meta-analysis reported only the length of the longer allele. Other potential factors that may 
lead to differing results is the usage of different genotyping methods and population 
differences and population stratification. Our results agree with a Belgian study that reported 
that intermediate-length alleles increase the risk of ALS only in those with two intermediate-
length alleles (OR 2.08, p=0.04)  (Gijselinck et al., 2016). Moreover, in a Flanders-Belgian 
cohort, the A/A genotype of rs3849942  was more common in FTLD patients without the 




The main limitations of this study were that achieving sufficient sample size requires pooling 
individuals from multiple cohorts. These cohorts had different demographic characteristics 
that can influence ALS risk and the rs3849942 genotyping platform varied. 
In future, the role of homozygous intermediate genotypes in ALS is worth studying more with 
bigger sample sizes and slightly different methodology. Amplified fragment length 
polymorphism PCR with only two primers might have better sensitivity in detecting 
homozygous samples than RP-PCR but it has poorer expansion detection. Another interesting 
question is, if Finns have some enriched genetic variation that e.g. controls expression of 
intermediate repeats and therefore their effect on ALS development is smaller than in other 
populations. Targeted resequencing coupled with haplotype analysis could elucidate this 
question.  
 
Table 5: Intermediate allele carrier frequencies in 525 ALS cases and 3950 controls (expansion carriers 
excluded). 
Longer allele Controls n ALS n p OR 95% CI 
7-45 1293 (33%) 185 (35%) 0.26 1.12 0.92-1.36 
17-45 101 (2.6%) 19 (3.6%) 0.15 1.43 0.82-2.74 
21-45 66 (1.7%) 12 (2.3%) 0.29 1.38 0.67-2.59 
24-45 43 (1.1%) 6 (1.1%) 0.82 1.05 0.36-2.50 













Table 6. Intermediate allele carrier frequencies in different control individual age groups. 
 





7-45 273 (31%) 657 (33%) 363 (33%) 0.46 
17-45  29 (3.3%)  44 (2.2%)  28 (2.5%) 0.33 
21-45  18 (2.1%)  29 (1.5%)  19 (1.7%) 0.62 
24-45 12 (1.4%)  17 (0.86%) 14  (1.3%) 0.92 
24-30 10 (1.1%) 9  (0.46%)  11 (1.0%) 0.85 
Size of age 
group 
873 1973 1102  
 
 
Table 7. Individuals with two intermediate-length alleles in 525 ALS patients and 3 950 controls after exclusion 
of expansion carriers. 




p OR 95% CI 
≥7/≥7 104 (2.6%) 26 (5.0%) 0.005 1.93 1.19-3.02 
7-16/7-16 94 (2.4%) 19 (3.6%) 0.098 1.57 0.90- 2.62 
≥7/17-45 10 (0.25%) 7 (1.3%) 0.0020 5.32 1.71-15.56 
≥7/21-45 3 (0.076%) 6 (1.1%) 0.00016 15.19 3.23-94.21 










4.3. Distribution and progression of LRP 
 
In the neuropathologically examined Vantaa85+ subsample, LRP was common. It was 
observed in 124/304 (41%) of individuals. LRP severity in the different anatomic sites was 
scored semiquantitatively. This allowed for 113/124 of the samples to be classified according 
to the DLB consortium guidelines: 19 had brainstem type, 10 amygdala-predominant type, 41 
limbic type, and 43 diffuse neocortical type. 
In addition to the DLB consortium guideline types, LRP showed two progression patterns: 
caudo-rostral and amygdala based. All but one sample could be classified into these 
progression patterns. Caudo-rostral progression was more prevalent (83/123) but amygdala-
based was also quite common, present in 40/123 (32%) of individuals with LRP.  
There was clear overlap with the DLB consortium classification and LRP progression pattern: 
95% of brainstem type had caudo-rostral progression and all amygdala-predominant type had 
the amygdala-base progression pattern. The overlap in limbic and diffuse neocortical types 
was more mixed. 
Further studies showed that amygdala-based progression associated with AD pathology. The 
most severe Braak NFT stages (V–VI) were more commonly observed with the amygdala-
based progression than with the caudo-rostral progression (Fisher’s test, p = 5.63e-8) or with 
no LRP (Fisher’s test, p = 1.05e-7). A moderate to frequent CERAD score was also more 
commonly observed with the amygdala-based progression than with the caudo-rostral 
progression (Fisher’s test, p=1.86e-5) or with no LRP (Fisher’s test, p=6.91e-6). There was no 
statistically significant difference (Fisher’s test p>0.05) in Braak NFT stages V-VI or moderate 
to frequent CERAD score between the caudo-rostral pattern (n = 83) and individuals with no 
LRP (n = 180). 
APOE ε4 genotype was more common in the amygdala-based progression pattern than in the 
caudo-rostral progression pattern (Fisher’s test, p = 0.001843) or in individuals with no LRP 
(Fisher’s test, p = 4.61e-5). There was no statistically significant difference in the APOE ε4 
genotype proportion between the caudo-rostral pattern and individuals with no LRP (Fisher’s 
test, p = 0.4457). 
In accordance with the previous results, significantly more people were demented in the 
amygdala-based progression pattern group than in the caudo-rostral group (Fisher’s test, p =  
4.48e-4) or in individuals with no LRP (Fisher’s test, p = 1.8e-5). A summary of the results is 








Table 7. Demographic, neuropathological and genetic differences between LRP classification schemes and their 
subgroups. 
 
No LRP (a) DLB Consortium classification n = 124 (b) LRP progression-














n 180 11 19 10 41 43 83 40 
Women (%) 85 82 84 90 80 74 76 88 
Mean age at 
death (years) 
92.3 91.3 93.8 93.0 92.3 92.2 92.6 92.3 
Age at death 
(n, %) 
        
 85–89 45 (25) 5 (46) 4 (21) 1 (10) 14 (34) 13 (30) 26 (31) 11 (28) 
 90–94 94 (52) 3 (27) 9 (47) 6 (60) 16 (39) 18 (42) 33 (40) 18 (45) 
 ≥ 95 41 (23) 3 (27) 6 (32) 3 (30) 11 (27) 12 (28) 24 (29) 11 (28) 
Braak NFT 
stage (n, %) 
        
 0-II 54 (30) 6 (55) 8 (42) 1 (10) 10 (24) 11 (26) 34 (41) 2 (5) 
 III–IV 92 (51) 3 (27) 8 (42) 5 (50) 20 (49) 14 (33) 36 (43) 13 (33) 
 V–VI 34 (19) 2 (18) 3 (16) 4 (40) 11 (27) 18 (42) 13 (16) 25 (63) 
CERAD score 
(n, %) 
        
 None 46 (26) 2 (18) 7 (37) 1 (10) 11 (27) 4 (9) 24 (29) 1 (3) 
 Sparse 24 (13) 1 (9) 3 (16) 0 (0) 3 (7) 2 (5) 9 (11) 0 (0) 
 Moderate–
frequent 
110 (61) 8 (73) 9 (47) 9 (90) 27 (66) 37 (86) 50 (60) 39 (98) 
NIA-RI (n, %) 
        
 No 32 (35) 3 (50) 7 (58) 0 (0) 7 (26) 4 (13) 21 (25) 0 (0) 
 Yes 59 (65) 3 (50) 5 (42) 7 (100) 20 (74) 26 (87) 24 (29) 36 (90) 
Dementia 
status at 
death (n,  %) 
        
 No 74 (41) 5 (45) 10 (53) 1 (10) 15 (37) 3 (7) 31 (37) 3 (8) 
 Yes 106 (59) 6 (55) 9 (47) 9 (90) 26 (63) 40 (93) 52 (63) 37 (93) 
APOE ε4 (n, 
%) 
        
 No 126 (74) 7 (70) 15 (79) 5 (56) 19 (53) 22 (55) 54 (65) 13 (33) 










DLB is the second most common primary neurodegenerative disease and our cohort study 
demonstrates again how common LRP is in very old populations. Despite being common, the 
etiology of DLB and LRP is still poorly understood as is its genetics. DLB has unclear overlap 
with AD and PDD, and so far the largest GWAS study on DLB found APOE, the most common 
risk factor for AD, to be the strongest association for DLB as well (Guerreiro et al., 2018). 
However, in our study, APOE did not universally associate with LRP as APOE ε4 did not 
associate with the caudo-rostral progression pattern, but only with amygdala-based LRP. We 
did not study DLB per se but the differences in LRP progression point to a biologically distinct 
AD-associated LRP type. 
Our findings raise the need to reanalyze DLB data with these two different subgroups in mind 
and provides an important piece of the puzzle in the relationship between APOE, AD 
pathology and α-synuclein pathology. One of the big questions has been whether APOE is an 
independent driver of α-synuclein pathology or whether its effects are mediated by AD 
pathology. Our data demonstrate that not all LRP is associated with APOE ε4, rather the 
association is seen in LRP when there is significant AD pathology. These findings suggest that 
APOE ε4 does not independently drive α-synuclein pathology, rather it increases the 
likelihood of Aβ and tau pathology which in turn can increase α-synuclein pathology. Our 
results are in line with what has been previously reported for APOE and Parkinson’s disease, 
another synucleinopathy like DLB: APOE was not associated with PD in a GWAS of tens of 
thousands of patients (Nalls et al., 2019). The caudo-rostral progression pattern of LRP is the 
one generally seen in PD and thus the lack of an association between APOE and PD is 
expected. 
Limitations of the study include that the required in-depth neuropathological analysis limits 
sample size. When studying multiple subgroups, some subgroups are therefore quite small. 
The semiquantitative LRP scoring is also susceptible to some subjectivity that could be 
reduced by scanning pathological sections and using image analysis software coupled with 
machine-learning. Furthermore, since neuropathological follow-up studies demonstrate the 
actual progression of LRP in time in one individual are impossible, other methods are needed 
to validate progression patterns at an individual level. One possibility is MRI imaging with 
biomarkers for α-synuclein, tau and Aβ. Especially as magnetic flux densities of MRI 
machines increase, more detailed information can be gathered from living patients. In future, 
the genetics of DLB subtypes should be studied beyond APOE e.g. via GWAS. Also, by 
studying the AD and PD polygenic risk scores of the subtypes it could be possible to assess in 









4.4. Alzheimer’s disease risk loci and neuropathological features 
 
To study how AD genetic risk loci associate with the neuropathologic features of AD, we used 
the neuropathological data from Vantaa85+ coupled with genotyped and imputed SNV data. 
We compared individuals with moderate or frequent CERAD scores with individuals with no 
neuritic plaques (CERAD 0). We compared individuals with Braak stages 0-II with individuals 
with Braak high stage (stages IV-VI). We compared individuals with capillary Aβ to those 
without it. We studied CAA as a continuous variable. The percentage of blood vessels with 
CAA of all blood vessels visible in the tissue slide was used as the variable. 
All candidate loci had variants either in the SNP array dataset or in the imputed dataset. We 
found an association (p<0.05) with most (24/29) AD risk loci with at least one of the AD 
pathological features. We could replicate the originally published index variants’ association 
in 7 of 44 variants. 
APOE ε4 was strongly associated with all the different neuropathological features (all p< 2.01 
e-7 and all OR/β> 6.49). In addition to APOE ε4, APP, MS4A cluster, NME8, SORL1, the 
chromosome 9 locus and SLC24A4 all associated with all neuropathological features. 
The top association with CERAD was MEF2C (rs700588) (when adjusted for age, sex, and 
APOE ε4, p = 0.0002122, OR 2.67, 95% CI 1.59–4.49) Other loci that associated with CERAD 
were ABCA7, ABCG1, APP, BIN1, FERMT2, GAB2, MSA4 CLUSTER, NME8, PICALM, 
PTK2B, SLC24A4, SORL1 and the chromosome 9 region. 
The top association with Braak staging was found with ABCG1 (rs532345, p = 0.02671, OR 
0.5571, 95% CI 0.33–0.93 with APOE ε4 adjustment). Other associations were ABCA7, APP, 
CASS4, CR1, GAB2, GALNT7, MEF2C, MS4A cluster, NME8, PTK2B, SLC24A4, SORL1, the 
chromosome 9 region and TRIP4. 
The top association with CAA was CR1 (rs65087, p = 0.004934, β 2.52, 95% CI 0.78–4.26 
without APOE ε4 adjustment. The other associating loci were ABCA7, ABCG1, APP, BIN1, 
CASS4, CD2AP, CLU, FERMT2, GAB2, GALNT7, HLA-DRB1, MSA4 cluster, NME8, PICALM, 
SLC24A4, SORL1, the chromosome 9 region, TRIP4 and ZCWPW1. 
The top association with capillary Aβ was APP (rs1783016, p = 0.005933, OR 2.01, 95% CI 
1.22–3.30 with APOE ε4 adjustment). The other loci with association were BIN1, CR1, 
FERMT2, GALNT7, HLA-DRB1, HLA-DRB5, MSA4 cluster, NME8, PICALM, PTK2B, SORL1, 
the chromosome 9 region and TREM2. 






Table 8. Summary of results. Results with (a) and without (b) APOE ε4 carrier status as a covariate. Genes that 
associated with AD in the two new large AD GWAS meta-analyses (Jansen et al., 2019; Kunkle et al., 2019) are in 
bold. 
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Our results suggest that some AD loci play a role in the development of all AD 
neuropathological features while some with only one. This view is supported by new pathway 
analyses that show that some genes (e.g. APOE) are part of many of the AD molecular 
pathways whereas some are more specific to one pathway (Kunkle et al., 2019). We were 
among the first to study capillary Aβ and it was noteworthy that the associated loci of CAA 
and capAβ did not completely overlap. This suggests some differences in the underlying 
neuropathological mechanisms of these two neuropathologic changes. 
This study has also limitations. Imputation was performed with a multinational reference 
panel. A population-specific imputation reference panel would most likely have allowed better 
imputation quality especially for rare variants. Another consideration is the need and 
methodology for multiple testing corrections. Since this was a replication study, we used p = 
0.05 as the threshold for statistical significance. However, the larger and therefore the more 
variants a locus has, the more likely it is to have a variant to show spurious association. Newer 
bigger AD GWASes have also been published (Jansen et al., 2019; Kunkle et al., 2019) and not 
all loci we tested were replicated in them. These loci might be more population specific but, 
they may also be false positive observations in the previous studies. The newer AD GWASes 























The aim of this study was to study the genetics of three neurodegenerative diseases: ALS, AD 
and DLB. Special emphasis was on the C9orf72 hexanucleotide repeat and APOE. 
Publication I: 
Repeat lengths of over 20 seem to be more common in Finland than elsewhere, which raises 
the possibility that they function as premutations. The widely used pathogenic threshold of 30 
repeats might be too low. There was no statistically significant association between 
intermediate repeats and AD/cognitive impairment. 
Publication II: 
After publication I, more evidence on the potential role of C9orf72 intermediate repeats in the 
pathogenicity of ALS and CBD was reported. We found that carrying two intermediate-length 
alleles increases the risk of ALS whereas carrying just one intermediate-length allele does not. 
Publication III: 
We were able to confirm in a population-based study that there are two ways for LRP to 
progress: the caudo-rostral and amygdala-based patterns. There was a clear association of AD 
pathology with amygdala-based pattern but not with the caudo-rostral pattern. These findings 
confirm the previously hypothesized “Alzheimer associated LRP”. It also raises the need to 
reanalyze DLB genetic data with these two progression patterns in mind. 
Publication IV: 
Different AD risk loci associate with different AD neuropathologic features. Some associate 
with all neuropathological features while others with only one. Moreover, we were able to 
show risk loci for capillary Aβ. 
 
Overall, the results of this thesis elucidate the phenotypic effects of C9orf72 intermediate-
length alleles by showing that carrying one intermediate allele does not increase the risk of 
ALS or AD. However, carrying two intermediate-length alleles increases the risk of ALS. The 
results of this thesis also show that genes associated with AD show different association 
patterns with the neuropathological features of AD. Similarly, APOE ε4, the strongest 
association signal of DLB in multinational studies, associates only with one of the two 
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